,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2008', 'fs': 'Jun 2008', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRLUAY'}, 'Id': 'a0P2P000006pnRLUAY', 'Event_Date__c': '2008-06-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jun 2008', 'Status_History__c': 'a132P000000ApIsQAK'}, 'change': None}]",Jun 2008,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Jul 2008', 'fs': 'Jul 2008', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 23 July 2008.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 23 July 2008.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRMUAY'}, 'Id': 'a0P2P000006pnRMUAY', 'Event_Date__c': '2008-07-23', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 23 July 2008.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Jul 2008', 'Status_History__c': 'a132P000000ApK9QAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'No Formal Recommendation', 'fs': 'No Formal Recommendation', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">Endocrinology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">Endocrinology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2012', 'fs': 'May 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 29 May 2012.', 'fs': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 29 May 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRNUAY'}, 'Id': 'a0P2P000006pnRNUAY', 'Event_Date__c': '2012-05-29', 'Event_Description__c': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 29 May 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2012-05-29.pdf"" target=""_blank"">Endocrinology Subcommittee minutes</a>', 'Outcome__c': 'No Formal Recommendation', 'Formatted_Date__c': 'May 2012', 'Status_History__c': 'a132P000000Aq2sQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2014', 'fs': 'Dec 2014', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 2 December 2014.', 'fs': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 2 December 2014.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnROUAY'}, 'Id': 'a0P2P000006pnROUAY', 'Event_Date__c': '2014-12-02', 'Event_Description__c': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 2 December 2014.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Dec 2014', 'Status_History__c': 'a132P000000AqqVQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-02.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-02.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2015', 'fs': 'Feb 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Saturday 7 February 2015.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Saturday 7 February 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRPUAY'}, 'Id': 'a0P2P000006pnRPUAY', 'Event_Date__c': '2015-02-07', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Saturday 7 February 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-02.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Feb 2015', 'Status_History__c': 'a132P000000AqrWQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 November 2015.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 November 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRQUAY'}, 'Id': 'a0P2P000006pnRQUAY', 'Event_Date__c': '2015-11-05', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 November 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Nov 2015', 'Status_History__c': 'a132P000000Ar1SQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2016', 'fs': 'May 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRWUAY'}, 'Id': 'a0P2P000006pnRWUAY', 'Event_Date__c': '2016-05-05', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2016', 'Status_History__c': 'a132P000000Ar8FQAS'}, 'change': None}, {'Summary': {'s': 'The Committee recommended that the funding of cinacalcet in patients with non-malignant secondary hyperparathyroidism with symptomatic hypercalcaemia, including those patients contraindicated to surgery or where previous surgery has been unsuccessful, and regardless of whether or not the patient is on dialysis, be declined', 'fs': 'The Committee recommended that the funding of cinacalcet in patients with non-malignant secondary hyperparathyroidism with symptomatic hypercalcaemia, including those patients contraindicated to surgery or where previous surgery has been unsuccessful, and regardless of whether or not the patient is on dialysis, be declined', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2016', 'fs': 'May 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2016.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRXUAY'}, 'Id': 'a0P2P000006pnRXUAY', 'Event_Date__c': '2016-05-05', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Committee recommended that the funding of cinacalcet in patients with non-malignant secondary hyperparathyroidism with symptomatic hypercalcaemia, including those patients contraindicated to surgery or where previous surgery has been unsuccessful, and regardless of whether or not the patient is on dialysis, be declined', 'Formatted_Date__c': 'May 2016', 'Status_History__c': 'a132P000000Ar8HQAS'}, 'change': None}, {'Summary': {'s': 'The Subcommittee reiterated its previous recommendation with regards to proposed Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism.', 'fs': 'The Subcommittee reiterated its previous recommendation with regards to proposed Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Dec 2016', 'fs': 'Dec 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'fs': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRaUAI'}, 'Id': 'a0P2P000006pnRaUAI', 'Event_Date__c': '2016-12-06', 'Event_Description__c': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 6 December 2016.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'Outcome__c': 'High', 'Summary__c': 'The Subcommittee reiterated its previous recommendation with regards to proposed Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism.', 'Formatted_Date__c': 'Dec 2016', 'Status_History__c': 'a132P000000ArF1QAK'}, 'change': None}, {'Summary': {'s': 'The Committee noted the recommendation was based on the lack of evidence of a long-term clinical benefit in these patients. The Committee noted that the views of both the Endocrinology and Nephrology Subcommittees were taken into account in making its recommendations regarding funding for cinacalcet.', 'fs': 'The Committee noted the recommendation was based on the lack of evidence of a long-term clinical benefit in these patients. The Committee noted that the views of both the Endocrinology and Nephrology Subcommittees were taken into account in making its recommendations regarding funding for cinacalcet.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2017', 'fs': 'May 2017', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 May 2017.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 May 2017.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRbUAI'}, 'Id': 'a0P2P000006pnRbUAI', 'Event_Date__c': '2017-05-04', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 4 May 2017.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2017-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Committee noted the recommendation was based on the lack of evidence of a long-term clinical benefit in these patients. The Committee noted that the views of both the Endocrinology and Nephrology Subcommittees were taken into account in making its recommendations regarding funding for cinacalcet.', 'Formatted_Date__c': 'May 2017', 'Status_History__c': 'a132P000000ArHZQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2018-03.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2018-03.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2018', 'fs': 'Mar 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 20 March 2018.', 'fs': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 20 March 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRcUAI'}, 'Id': 'a0P2P000006pnRcUAI', 'Event_Date__c': '2018-03-20', 'Event_Description__c': 'Clinical advice received from Nephrology Subcommittee at meeting Tuesday 20 March 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2018-03.pdf"" target=""_blank"">Nephrology Subcommittee minutes</a>', 'Outcome__c': 'High', 'Formatted_Date__c': 'Mar 2018', 'Status_History__c': 'a132P000000ArR7QAK'}, 'change': None}, {'Summary': {'s': 'The Committee considered that more robust evidence of effectiveness would be required to modify its recommendation.', 'fs': 'The Committee considered that more robust evidence of effectiveness would be required to modify its recommendation.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-11.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-11.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2018', 'fs': 'Nov 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 1 November 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 1 November 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRdUAI'}, 'Id': 'a0P2P000006pnRdUAI', 'Event_Date__c': '2018-11-01', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 1 November 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-11.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Summary__c': 'The Committee considered that more robust evidence of effectiveness would be required to modify its recommendation.', 'Formatted_Date__c': 'Nov 2018', 'Status_History__c': 'a132P000000ArYxQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Endocrinology Subcommittee meeting to provide advice on Tuesday 30 March 2021', 'fs': 'Assigned to Endocrinology Subcommittee meeting to provide advice on Tuesday 30 March 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnReUAI'}, 'Id': 'a0P2P000006pnReUAI', 'Event_Date__c': '2021-02-19', 'Event_Description__c': 'Assigned to Endocrinology Subcommittee meeting to provide advice on Tuesday 30 March 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2021', 'Status_History__c': 'a132P000000CcRfQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 20 August 2021', 'fs': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 20 August 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRfUAI'}, 'Id': 'a0P2P000006pnRfUAI', 'Event_Date__c': '2021-06-10', 'Event_Description__c': 'Assigned to Pharmacology and Therapeutics Advisory Committee (PTAC) meeting to provide advice on Friday 20 August 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000DNqIQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRgUAI'}, 'Id': 'a0P2P000006pnRgUAI', 'Event_Date__c': '2021-06-18', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000Cw3oQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<p>Discussion</p><p>1.1.\xa0\xa0\xa0The Subcommittee considered that the target patient population is a subset of the population with primary hyperparathyroidism with hypercalcaemia; the target group is either unsuitable for surgery, have declined surgery or have not benefitted from surgery and have significant hypercalcaemia, defined as albumin-adjusted calcium &gt;3.0 mmol/L with or without symptoms of hypercalcaemia, or &gt;2.85 mmol/L with symptoms of hypercalcaemia (consistent with the definition used in the NICE guidelines for primary hyperparathyroidism in the UK and Wales; NICE, 2019). The Subcommittee noted the potential for minor variability in laboratory test values across the country but considered &gt;3.0 mmol/L and &gt;2.85 mmol/L to be reasonable thresholds for defining this population.\xa0</p><p><br></p><p>1.2.\xa0\xa0The Subcommittee considered that these patients may present with a wide range of clinical manifestations non-specific to primary hyperparathyroidism itself (eg persistent hypercalcaemia, fracture, renal stones, hypercalciuria, osteoporosis), and may include a neurocognitive presentation with psychotic episodes occurring every few months. The Subcommittee noted that people with primary hypercalcaemia are also at risk of excess death from heart or lung causes. The Subcommittee considered that people with acute symptomatic hypercalcaemia may also require acute interventions for management.</p><p><br></p><p>1.3.\xa0\xa0The Subcommittee estimated that the target group may consist of 6-10 new patients per year nationwide, based on case numbers in Auckland and Christchurch. The Subcommittee considered that most of these patients would likely require treatment when aged in their 70s and 80s and therefore some annual mortality would also be expected, and a very small number of patients may require treatment for many years. The Subcommittee considered that an exceptional number of patients (less than one per year) with rare genetic syndromes might require treatment from a younger age. The Subcommittee considered a patient deemed as not being operable (ie not a candidate for surgery) would likely be considered non-operable for life.\xa0</p><p><br></p><p>1.4.\xa0\xa0Members noted the surgical procedure is complex and, in some patients, may not be deemed feasible or suitable in the surgical or multi-disciplinary team’s opinion (eg due to co-morbidities), or surgery may not be successful in achieving the intended clinical outcomes. In addition, the Subcommittee noted that not all patients may judge their proposed surgery to be beneficial when compared with its risks, and thus that informed consent may not be provided by these patients for anaesthesia and the surgical procedure itself.</p><p><br></p><p>1.5.\xa0\xa0The Subcommittee considered that there is a lack of evidence to inform whether primary hyperparathyroidism disproportionately affects Māori and Pacific peoples, although noted that these populations may experience greater comorbidity than non-Māori and non-Pacific people.</p><p><br></p><p>1.6.\xa0\xa0\xa0\xa0The Subcommittee noted that cinacalcet is taken orally and can be titrated to achieve a reduction in calcium levels to below 3.0 mmol/L and/or treatment of symptoms. The Subcommittee considered that there is evidence that elevated calcium levels are associated with symptoms, and that a reduction in calcium level is associated with symptom improvement. The Subcommittee considered the goal of treatment in this patient group is to reduce serum calcium levels to &lt;3.0 mmol/L (rather than reducing parathyroid hormone levels), as &lt;3.0 mmol/L is considered a ‘safe’ serum calcium level that reduces the risks of neurocognitive complications of hypercalcaemia, and of episodes of acute severe hypercalcemia.</p><p><br></p><p>1.7.\xa0\xa0\xa0\xa0The Subcommittee considered that new evidence to inform the assessment of cinacalcet in this primary hyperparathyroidism was limited, however, members were made aware of evidence from the following publications (of which, two include cinacalcet for parathyroidectomy non-candidates which referred to hypercalcaemia with unspecified severe symptoms):</p><p><br></p><p>1.7.1.\xa0\xa0\xa0\xa0\xa0The Subcommittee noted an observational cohort study (audit) in Scotland of 2,598 surgical patients admitted with primary hyperparathyroidism (causes of secondary hyperparathyroidism being excluded) between 1986 to 2010 with data followed up until 2011 and including post-surgery outcomes for those who received parathyroidectomy (Collier et al. Endocr Pract. 2019;25:335-9). The Subcommittee noted that 78% of patients included were female, which the Subcommittee considered was a reasonable estimate of female prevalence in this disease.\xa0</p><p><br></p><p>1.7.1.1.\xa0\xa0\xa0The Subcommittee noted that after follow-up, 41% of the total cohort were deceased and the standardised mortality ratio compared with the general population was 1.58, but that 42% of patients did not have surgery (either they did not meet criteria, or for other reasons), and therefore considered this group was more conservatively treated group than those in New Zealand.\xa0</p><p><br></p><p>1.7.1.2.\xa0\xa0\xa0The Subcommittee noted that the raw standardised mortality ratio compared to the general population was 1.30 in patients who received surgery (58% of the cohort) and was 1.88 in patients who were treated conservatively; after adjustment for comorbidity, the latter reduced to 1.49 (95% CI: 1.30 to 1.70; P&lt;.0001). The Subcommittee considered the conservatively treated group was similar to the target New Zealand population for this indication. Based on this, the Subcommittee considered that hyperparathyroidism increases mortality compared with the general population; that surgery can reduce this mortality; and therefore, that it was reasonable to infer that cinacalcet may provide the same or similar benefit as surgery by reducing mortality by reducing serum calcium levels.</p><p><br></p><p>1.7.2.\xa0\xa0\xa0\xa0The Subcommittee was made aware of a systematic review and meta regression of cinacalcet in primary hyperparathyroidism (Ng et al. Endocr Connect. 2020;9:724-35) which included eight trials, none of which the Subcommittee considered provided new information as all had been considered by PTAC or PTAC Subcommittees previously. The Subcommittee noted that 90% of patients had normalisation of calcium levels and 10% had normalisation of parathyroid hormone, however, no other endpoints (eg quality of life) or outcomes for mortality and morbidity were discussed in the publication.\xa0</p><p><br></p><p>1.7.3.\xa0\xa0\xa0\xa0The Subcommittee was made aware of an 8-year retrospective observational cohort study in Scotland of 611 patients with primary hyperparathyroidism seen in secondary care between 2006 and 2014, of which 337 patients did not receive surgery (Reid et al. J Clin Endocrinol Metab. 2019;104:3692-700). The Subcommittee noted that after an 8-year period of follow-up, the mortality rate was 16.0% (98/611) overall, with about 30% of deaths due to cancer and about 30% due to cardiovascular disease. The Subcommittee noted that 79 deaths were reported in the group who did not receive surgery. The Subcommittee noted associations between mortality and increasing age, social deprivation, and elevated adjusted calcium levels at diagnosis that were statistically significant, but no associations with parathyroid hormone levels at diagnosis. The Subcommittee considered that the study population was similar to the target New Zealand population for this indication and was the most representative evidence for the target New Zealand population. The Subcommittee considered it may not be feasible to do an appropriately powered intervention study in this population.\xa0</p><p><br></p><p>1.7.4.\xa0\xa0\xa0\xa0The Subcommittee noted an observational cohort study derived from a random population sample of 750 50-year-old men in Sweden that described a 21 year follow up of men with primary hyperparathyroidism, and which did not show evidence for long term complications nor a mortality difference. The Subcommittee noted this study reported very wide confidence intervals (Kontogeorgos et al. Scand J Clin Lab Invest. 2020;80:6-13).\xa0</p><p><br></p><p>1.8.\xa0\xa0\xa0\xa0The Subcommittee noted that UpToDate suggests cinacalcet be used for patients with symptomatic primary hyperparathyroidism who are unable to have surgery (whose primary indication for surgery is symptomatic and/or severe hypercalcemia), and that cinacalcet would be more appropriate than bisphosphonates where bone density is normal, as supported by literature review updated in April 2021.\xa0</p><p><br></p><p>1.9.\xa0\xa0\xa0\xa0The Subcommittee noted that the previously mentioned NICE guidelines for primary hyperparathyroidism in the UK and Wales (NICE, 2019) recommend cinacalcet be used for patients in whom surgery fails or is denied, to treat symptomatic patients with calcium over 2.85 mmol/L and patients with calcium levels of &gt;3.0 mmol/L with or without symptoms. Members noted that the NICE guidelines state that bisphosphonates should not be used for chronic hypercalcaemia of primary hyperparathyroidism.</p><p><br></p><p>1.10.\xa0\xa0\xa0The Subcommittee considered that there is evidence of improved mortality from secondary hyperparathyroidism in patients on renal dialysis in particular, and that this comorbid population experiences high event rates and pathology-related mortality from hypercalcaemia and secondary hyperparathyroidism, due to the toxicity of the parathyroid hormone.\xa0</p><p><br></p><p>1.11.\xa0\xa0\xa0Overall, the Subcommittee considered that existing evidence for efficacy of cinacalcet in reducing serum calcium in primary hyperparathyroidism is robust. The Subcommittee considered the health benefit for hypercalcaemia is based on biochemical and end-organ endpoints after surgery (which the Subcommittee considered provides strong evidence), and that there is a lack of evidence for reduced mortality in the population with primary hypercalcaemia following treatment with cinacalcet.</p><p><br></p><p>1.12.\xa0\xa0\xa0The Subcommittee considered that there was no new evidence of biochemical efficacy of cinacalcet in reducing serum calcium, although existing evidence for this is robust and that there was strong evidence for cinacalcet compared with surgery in normalising calcium levels (but not in reducing parathyroid hormone levels).\xa0</p><p><br></p><p>Summary</p><p><br></p><p>1.13.\xa0\xa0\xa0The Subcommittee considered that a reduction in calcium to less than 3.0 mmol/L was clinically meaningful and a critical outcome for the target group of patients with primary hyperparathyroidism, whereas that a reduction in parathyroid hormone was not the target outcome for this group.\xa0</p><p><br></p><p>1.14.\xa0\xa0\xa0The Subcommittee considered that it was reasonable to infer, based on the evidence of benefits (including reduction in mortality) from calcium level reduction (from surgery and from the use of cinacalcet in several hypercalcaemic states), that cinacalcet could result in clinically meaningful benefits from a calcium level reduction in people with primary hyperparathyroidism who are not deemed operable. The Subcommittee considered that, while there was limited evidence for the effect of cinacalcet on endpoints such as cardiovascular outcomes, fractures and mortality, it was reasonable to assume that a clinically significant reduction in calcium levels would be associated with improvement in these endpoints.</p><p><br></p><p>1.15.\xa0\xa0\xa0The Subcommittee considered it reasonable for cinacalcet to be funded for people with primary hyperparathyroidism with severe hypercalcemia who are not deemed operable, and have no available alternative treatments. Members noted many such patients would experience neurocognitive effects from elevated calcium. The Subcommittee considered that if funded for this population, cinacalcet would be a chronic intervention to keep calcium low and that, if tolerated and effective in reducing calcium levels, treatment with cinacalcet could be lifelong, or otherwise treatment would be discontinued.\xa0</p><p><br></p><p>1.16.\xa0\xa0\xa0The Subcommittee noted that there was a lack of evidence to inform the frequency and management of interventions to manage acute symptomatic hypercalcaemia, which would incur clinical costs for close observation, monitoring and short-term management. The Subcommittee considered that data regarding quality of life, long-term complications and hospitalisations is not available within the published clinical trial evidence and would need to be obtained from authoritative guidelines and clinician advice.\xa0</p><p><br></p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, if criteria were to be applied to target funding of cinacalcet to this population with primary hyperparathyroidism, all the following would need to be incorporated: hypercalcaemia of &gt;3 mmol/L with or without symptoms, or &gt;2.85 mmol/L with symptoms; the patient is not deemed operable, or surgery has failed or is contraindicated; and the patient has other comorbidities, severe bone pain, or calciphylaxis.</p>', 'fs': '<p>Discussion</p><p>1.1.\xa0\xa0\xa0The Subcommittee considered that the target patient population is a subset of the population with primary hyperparathyroidism with hypercalcaemia; the target group is either unsuitable for surgery, have declined surgery or have not benefitted from surgery and have significant hypercalcaemia, defined as albumin-adjusted calcium &gt;3.0 mmol/L with or without symptoms of hypercalcaemia, or &gt;2.85 mmol/L with symptoms of hypercalcaemia (consistent with the definition used in the NICE guidelines for primary hyperparathyroidism in the UK and Wales; NICE, 2019). The Subcommittee noted the potential for minor variability in laboratory test values across the country but considered &gt;3.0 mmol/L and &gt;2.85 mmol/L to be reasonable thresholds for defining this population.\xa0</p><p><br></p><p>1.2.\xa0\xa0The Subcommittee considered that these patients may present with a wide range of clinical manifestations non-specific to primary hyperparathyroidism itself (eg persistent hypercalcaemia, fracture, renal stones, hypercalciuria, osteoporosis), and may include a neurocognitive presentation with psychotic episodes occurring every few months. The Subcommittee noted that people with primary hypercalcaemia are also at risk of excess death from heart or lung causes. The Subcommittee considered that people with acute symptomatic hypercalcaemia may also require acute interventions for management.</p><p><br></p><p>1.3.\xa0\xa0The Subcommittee estimated that the target group may consist of 6-10 new patients per year nationwide, based on case numbers in Auckland and Christchurch. The Subcommittee considered that most of these patients would likely require treatment when aged in their 70s and 80s and therefore some annual mortality would also be expected, and a very small number of patients may require treatment for many years. The Subcommittee considered that an exceptional number of patients (less than one per year) with rare genetic syndromes might require treatment from a younger age. The Subcommittee considered a patient deemed as not being operable (ie not a candidate for surgery) would likely be considered non-operable for life.\xa0</p><p><br></p><p>1.4.\xa0\xa0Members noted the surgical procedure is complex and, in some patients, may not be deemed feasible or suitable in the surgical or multi-disciplinary team’s opinion (eg due to co-morbidities), or surgery may not be successful in achieving the intended clinical outcomes. In addition, the Subcommittee noted that not all patients may judge their proposed surgery to be beneficial when compared with its risks, and thus that informed consent may not be provided by these patients for anaesthesia and the surgical procedure itself.</p><p><br></p><p>1.5.\xa0\xa0The Subcommittee considered that there is a lack of evidence to inform whether primary hyperparathyroidism disproportionately affects Māori and Pacific peoples, although noted that these populations may experience greater comorbidity than non-Māori and non-Pacific people.</p><p><br></p><p>1.6.\xa0\xa0\xa0\xa0The Subcommittee noted that cinacalcet is taken orally and can be titrated to achieve a reduction in calcium levels to below 3.0 mmol/L and/or treatment of symptoms. The Subcommittee considered that there is evidence that elevated calcium levels are associated with symptoms, and that a reduction in calcium level is associated with symptom improvement. The Subcommittee considered the goal of treatment in this patient group is to reduce serum calcium levels to &lt;3.0 mmol/L (rather than reducing parathyroid hormone levels), as &lt;3.0 mmol/L is considered a ‘safe’ serum calcium level that reduces the risks of neurocognitive complications of hypercalcaemia, and of episodes of acute severe hypercalcemia.</p><p><br></p><p>1.7.\xa0\xa0\xa0\xa0The Subcommittee considered that new evidence to inform the assessment of cinacalcet in this primary hyperparathyroidism was limited, however, members were made aware of evidence from the following publications (of which, two include cinacalcet for parathyroidectomy non-candidates which referred to hypercalcaemia with unspecified severe symptoms):</p><p><br></p><p>1.7.1.\xa0\xa0\xa0\xa0\xa0The Subcommittee noted an observational cohort study (audit) in Scotland of 2,598 surgical patients admitted with primary hyperparathyroidism (causes of secondary hyperparathyroidism being excluded) between 1986 to 2010 with data followed up until 2011 and including post-surgery outcomes for those who received parathyroidectomy (Collier et al. Endocr Pract. 2019;25:335-9). The Subcommittee noted that 78% of patients included were female, which the Subcommittee considered was a reasonable estimate of female prevalence in this disease.\xa0</p><p><br></p><p>1.7.1.1.\xa0\xa0\xa0The Subcommittee noted that after follow-up, 41% of the total cohort were deceased and the standardised mortality ratio compared with the general population was 1.58, but that 42% of patients did not have surgery (either they did not meet criteria, or for other reasons), and therefore considered this group was more conservatively treated group than those in New Zealand.\xa0</p><p><br></p><p>1.7.1.2.\xa0\xa0\xa0The Subcommittee noted that the raw standardised mortality ratio compared to the general population was 1.30 in patients who received surgery (58% of the cohort) and was 1.88 in patients who were treated conservatively; after adjustment for comorbidity, the latter reduced to 1.49 (95% CI: 1.30 to 1.70; P&lt;.0001). The Subcommittee considered the conservatively treated group was similar to the target New Zealand population for this indication. Based on this, the Subcommittee considered that hyperparathyroidism increases mortality compared with the general population; that surgery can reduce this mortality; and therefore, that it was reasonable to infer that cinacalcet may provide the same or similar benefit as surgery by reducing mortality by reducing serum calcium levels.</p><p><br></p><p>1.7.2.\xa0\xa0\xa0\xa0The Subcommittee was made aware of a systematic review and meta regression of cinacalcet in primary hyperparathyroidism (Ng et al. Endocr Connect. 2020;9:724-35) which included eight trials, none of which the Subcommittee considered provided new information as all had been considered by PTAC or PTAC Subcommittees previously. The Subcommittee noted that 90% of patients had normalisation of calcium levels and 10% had normalisation of parathyroid hormone, however, no other endpoints (eg quality of life) or outcomes for mortality and morbidity were discussed in the publication.\xa0</p><p><br></p><p>1.7.3.\xa0\xa0\xa0\xa0The Subcommittee was made aware of an 8-year retrospective observational cohort study in Scotland of 611 patients with primary hyperparathyroidism seen in secondary care between 2006 and 2014, of which 337 patients did not receive surgery (Reid et al. J Clin Endocrinol Metab. 2019;104:3692-700). The Subcommittee noted that after an 8-year period of follow-up, the mortality rate was 16.0% (98/611) overall, with about 30% of deaths due to cancer and about 30% due to cardiovascular disease. The Subcommittee noted that 79 deaths were reported in the group who did not receive surgery. The Subcommittee noted associations between mortality and increasing age, social deprivation, and elevated adjusted calcium levels at diagnosis that were statistically significant, but no associations with parathyroid hormone levels at diagnosis. The Subcommittee considered that the study population was similar to the target New Zealand population for this indication and was the most representative evidence for the target New Zealand population. The Subcommittee considered it may not be feasible to do an appropriately powered intervention study in this population.\xa0</p><p><br></p><p>1.7.4.\xa0\xa0\xa0\xa0The Subcommittee noted an observational cohort study derived from a random population sample of 750 50-year-old men in Sweden that described a 21 year follow up of men with primary hyperparathyroidism, and which did not show evidence for long term complications nor a mortality difference. The Subcommittee noted this study reported very wide confidence intervals (Kontogeorgos et al. Scand J Clin Lab Invest. 2020;80:6-13).\xa0</p><p><br></p><p>1.8.\xa0\xa0\xa0\xa0The Subcommittee noted that UpToDate suggests cinacalcet be used for patients with symptomatic primary hyperparathyroidism who are unable to have surgery (whose primary indication for surgery is symptomatic and/or severe hypercalcemia), and that cinacalcet would be more appropriate than bisphosphonates where bone density is normal, as supported by literature review updated in April 2021.\xa0</p><p><br></p><p>1.9.\xa0\xa0\xa0\xa0The Subcommittee noted that the previously mentioned NICE guidelines for primary hyperparathyroidism in the UK and Wales (NICE, 2019) recommend cinacalcet be used for patients in whom surgery fails or is denied, to treat symptomatic patients with calcium over 2.85 mmol/L and patients with calcium levels of &gt;3.0 mmol/L with or without symptoms. Members noted that the NICE guidelines state that bisphosphonates should not be used for chronic hypercalcaemia of primary hyperparathyroidism.</p><p><br></p><p>1.10.\xa0\xa0\xa0The Subcommittee considered that there is evidence of improved mortality from secondary hyperparathyroidism in patients on renal dialysis in particular, and that this comorbid population experiences high event rates and pathology-related mortality from hypercalcaemia and secondary hyperparathyroidism, due to the toxicity of the parathyroid hormone.\xa0</p><p><br></p><p>1.11.\xa0\xa0\xa0Overall, the Subcommittee considered that existing evidence for efficacy of cinacalcet in reducing serum calcium in primary hyperparathyroidism is robust. The Subcommittee considered the health benefit for hypercalcaemia is based on biochemical and end-organ endpoints after surgery (which the Subcommittee considered provides strong evidence), and that there is a lack of evidence for reduced mortality in the population with primary hypercalcaemia following treatment with cinacalcet.</p><p><br></p><p>1.12.\xa0\xa0\xa0The Subcommittee considered that there was no new evidence of biochemical efficacy of cinacalcet in reducing serum calcium, although existing evidence for this is robust and that there was strong evidence for cinacalcet compared with surgery in normalising calcium levels (but not in reducing parathyroid hormone levels).\xa0</p><p><br></p><p>Summary</p><p><br></p><p>1.13.\xa0\xa0\xa0The Subcommittee considered that a reduction in calcium to less than 3.0 mmol/L was clinically meaningful and a critical outcome for the target group of patients with primary hyperparathyroidism, whereas that a reduction in parathyroid hormone was not the target outcome for this group.\xa0</p><p><br></p><p>1.14.\xa0\xa0\xa0The Subcommittee considered that it was reasonable to infer, based on the evidence of benefits (including reduction in mortality) from calcium level reduction (from surgery and from the use of cinacalcet in several hypercalcaemic states), that cinacalcet could result in clinically meaningful benefits from a calcium level reduction in people with primary hyperparathyroidism who are not deemed operable. The Subcommittee considered that, while there was limited evidence for the effect of cinacalcet on endpoints such as cardiovascular outcomes, fractures and mortality, it was reasonable to assume that a clinically significant reduction in calcium levels would be associated with improvement in these endpoints.</p><p><br></p><p>1.15.\xa0\xa0\xa0The Subcommittee considered it reasonable for cinacalcet to be funded for people with primary hyperparathyroidism with severe hypercalcemia who are not deemed operable, and have no available alternative treatments. Members noted many such patients would experience neurocognitive effects from elevated calcium. The Subcommittee considered that if funded for this population, cinacalcet would be a chronic intervention to keep calcium low and that, if tolerated and effective in reducing calcium levels, treatment with cinacalcet could be lifelong, or otherwise treatment would be discontinued.\xa0</p><p><br></p><p>1.16.\xa0\xa0\xa0The Subcommittee noted that there was a lack of evidence to inform the frequency and management of interventions to manage acute symptomatic hypercalcaemia, which would incur clinical costs for close observation, monitoring and short-term management. The Subcommittee considered that data regarding quality of life, long-term complications and hospitalisations is not available within the published clinical trial evidence and would need to be obtained from authoritative guidelines and clinician advice.\xa0</p><p><br></p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, if criteria were to be applied to target funding of cinacalcet to this population with primary hyperparathyroidism, all the following would need to be incorporated: hypercalcaemia of &gt;3 mmol/L with or without symptoms, or &gt;2.85 mmol/L with symptoms; the patient is not deemed operable, or surgery has failed or is contraindicated; and the patient has other comorbidities, severe bone pain, or calciphylaxis.</p>', 'change': None}, 'Published_Application': {'s': '<h2><b>Background</b></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinical advice regarding cinacalcet for the treatment of hyperparathyroidism has been sought from PTAC and PTAC Subcommittees on many occasions from 2008 to 2016 (refer to the PHARMAC <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptsL/p000137"" target=""_blank"">Application Tracker</a> for full information).</p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there was a history of Exceptional Circumstances (EC) applications, and subsequently, Named Patient Pharmaceutical Assessments (NPPA) applications for cinacalcet for hyperparathyroidism, including primary hyperparathyroidism. The Subcommittee noted that, by 2015, PHARMAC staff had developed decision maker-approved criteria to guide their assessment of cinacalcet NPPA applications and that the volume of cinacalcet NPPA applications led PHARMAC to previously seek clinical advice to inform its consideration of a Pharmaceutical Schedule listing for cinacalcet.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the most recent advice from <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC in May 2016</a> recommended that funding of cinacalcet in the Pharmaceutical Schedule for patients with non-malignant primary hyperparathyroidism with symptomatic hypercalcaemia contraindicated to surgery, or where previous surgery has been unsuccessful, be declined. At that time, PTAC considered that insufficient new evidence had been provided to support a positive funding recommendation, and PTAC had considered that it was not appropriate to extrapolate the evidence in patients with parathyroid carcinoma, as this was a different disease.</p><p><br></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinically there is a strong desire for cinacalcet to be funded for the treatment of primary hyperparathyroidism in this patient group despite the lack of direct evidence of its effect on mortality and morbidity. The Subcommittee noted that PHARMAC had requested additional advice to help it assess and determine the next best steps for cinacalcet for the treatment of primary hyperparathyroidism.\xa0</p>', 'fs': '<h2><b>Background</b></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinical advice regarding cinacalcet for the treatment of hyperparathyroidism has been sought from PTAC and PTAC Subcommittees on many occasions from 2008 to 2016 (refer to the PHARMAC <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptsL/p000137"" target=""_blank"">Application Tracker</a> for full information).</p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there was a history of Exceptional Circumstances (EC) applications, and subsequently, Named Patient Pharmaceutical Assessments (NPPA) applications for cinacalcet for hyperparathyroidism, including primary hyperparathyroidism. The Subcommittee noted that, by 2015, PHARMAC staff had developed decision maker-approved criteria to guide their assessment of cinacalcet NPPA applications and that the volume of cinacalcet NPPA applications led PHARMAC to previously seek clinical advice to inform its consideration of a Pharmaceutical Schedule listing for cinacalcet.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the most recent advice from <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC in May 2016</a> recommended that funding of cinacalcet in the Pharmaceutical Schedule for patients with non-malignant primary hyperparathyroidism with symptomatic hypercalcaemia contraindicated to surgery, or where previous surgery has been unsuccessful, be declined. At that time, PTAC considered that insufficient new evidence had been provided to support a positive funding recommendation, and PTAC had considered that it was not appropriate to extrapolate the evidence in patients with parathyroid carcinoma, as this was a different disease.</p><p><br></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinically there is a strong desire for cinacalcet to be funded for the treatment of primary hyperparathyroidism in this patient group despite the lack of direct evidence of its effect on mortality and morbidity. The Subcommittee noted that PHARMAC had requested additional advice to help it assess and determine the next best steps for cinacalcet for the treatment of primary hyperparathyroidism.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">Endocrinology Subcommittee Records</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">Endocrinology Subcommittee Records</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 30 March 2021.', 'fs': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 30 March 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRhUAI'}, 'Id': 'a0P2P000006pnRhUAI', 'Event_Date__c': '2021-06-28', 'Event_Description__c': 'Clinical advice received from Endocrinology Subcommittee at meeting Tuesday 30 March 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">Endocrinology Subcommittee Records</a></p>', 'Formatted_Date__c': 'Jun 2021', 'Published_Application__c': '<h2><b>Background</b></h2><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinical advice regarding cinacalcet for the treatment of hyperparathyroidism has been sought from PTAC and PTAC Subcommittees on many occasions from 2008 to 2016 (refer to the PHARMAC <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptsL/p000137"" target=""_blank"">Application Tracker</a> for full information).</p><p><br></p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there was a history of Exceptional Circumstances (EC) applications, and subsequently, Named Patient Pharmaceutical Assessments (NPPA) applications for cinacalcet for hyperparathyroidism, including primary hyperparathyroidism. The Subcommittee noted that, by 2015, PHARMAC staff had developed decision maker-approved criteria to guide their assessment of cinacalcet NPPA applications and that the volume of cinacalcet NPPA applications led PHARMAC to previously seek clinical advice to inform its consideration of a Pharmaceutical Schedule listing for cinacalcet.</p><p><br></p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the most recent advice from <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC in May 2016</a> recommended that funding of cinacalcet in the Pharmaceutical Schedule for patients with non-malignant primary hyperparathyroidism with symptomatic hypercalcaemia contraindicated to surgery, or where previous surgery has been unsuccessful, be declined. At that time, PTAC considered that insufficient new evidence had been provided to support a positive funding recommendation, and PTAC had considered that it was not appropriate to extrapolate the evidence in patients with parathyroid carcinoma, as this was a different disease.</p><p><br></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that clinically there is a strong desire for cinacalcet to be funded for the treatment of primary hyperparathyroidism in this patient group despite the lack of direct evidence of its effect on mortality and morbidity. The Subcommittee noted that PHARMAC had requested additional advice to help it assess and determine the next best steps for cinacalcet for the treatment of primary hyperparathyroidism.\xa0</p>', 'Published_Discussion__c': '<p>Discussion</p><p>1.1.\xa0\xa0\xa0The Subcommittee considered that the target patient population is a subset of the population with primary hyperparathyroidism with hypercalcaemia; the target group is either unsuitable for surgery, have declined surgery or have not benefitted from surgery and have significant hypercalcaemia, defined as albumin-adjusted calcium &gt;3.0 mmol/L with or without symptoms of hypercalcaemia, or &gt;2.85 mmol/L with symptoms of hypercalcaemia (consistent with the definition used in the NICE guidelines for primary hyperparathyroidism in the UK and Wales; NICE, 2019). The Subcommittee noted the potential for minor variability in laboratory test values across the country but considered &gt;3.0 mmol/L and &gt;2.85 mmol/L to be reasonable thresholds for defining this population.\xa0</p><p><br></p><p>1.2.\xa0\xa0The Subcommittee considered that these patients may present with a wide range of clinical manifestations non-specific to primary hyperparathyroidism itself (eg persistent hypercalcaemia, fracture, renal stones, hypercalciuria, osteoporosis), and may include a neurocognitive presentation with psychotic episodes occurring every few months. The Subcommittee noted that people with primary hypercalcaemia are also at risk of excess death from heart or lung causes. The Subcommittee considered that people with acute symptomatic hypercalcaemia may also require acute interventions for management.</p><p><br></p><p>1.3.\xa0\xa0The Subcommittee estimated that the target group may consist of 6-10 new patients per year nationwide, based on case numbers in Auckland and Christchurch. The Subcommittee considered that most of these patients would likely require treatment when aged in their 70s and 80s and therefore some annual mortality would also be expected, and a very small number of patients may require treatment for many years. The Subcommittee considered that an exceptional number of patients (less than one per year) with rare genetic syndromes might require treatment from a younger age. The Subcommittee considered a patient deemed as not being operable (ie not a candidate for surgery) would likely be considered non-operable for life.\xa0</p><p><br></p><p>1.4.\xa0\xa0Members noted the surgical procedure is complex and, in some patients, may not be deemed feasible or suitable in the surgical or multi-disciplinary team’s opinion (eg due to co-morbidities), or surgery may not be successful in achieving the intended clinical outcomes. In addition, the Subcommittee noted that not all patients may judge their proposed surgery to be beneficial when compared with its risks, and thus that informed consent may not be provided by these patients for anaesthesia and the surgical procedure itself.</p><p><br></p><p>1.5.\xa0\xa0The Subcommittee considered that there is a lack of evidence to inform whether primary hyperparathyroidism disproportionately affects Māori and Pacific peoples, although noted that these populations may experience greater comorbidity than non-Māori and non-Pacific people.</p><p><br></p><p>1.6.\xa0\xa0\xa0\xa0The Subcommittee noted that cinacalcet is taken orally and can be titrated to achieve a reduction in calcium levels to below 3.0 mmol/L and/or treatment of symptoms. The Subcommittee considered that there is evidence that elevated calcium levels are associated with symptoms, and that a reduction in calcium level is associated with symptom improvement. The Subcommittee considered the goal of treatment in this patient group is to reduce serum calcium levels to &lt;3.0 mmol/L (rather than reducing parathyroid hormone levels), as &lt;3.0 mmol/L is considered a ‘safe’ serum calcium level that reduces the risks of neurocognitive complications of hypercalcaemia, and of episodes of acute severe hypercalcemia.</p><p><br></p><p>1.7.\xa0\xa0\xa0\xa0The Subcommittee considered that new evidence to inform the assessment of cinacalcet in this primary hyperparathyroidism was limited, however, members were made aware of evidence from the following publications (of which, two include cinacalcet for parathyroidectomy non-candidates which referred to hypercalcaemia with unspecified severe symptoms):</p><p><br></p><p>1.7.1.\xa0\xa0\xa0\xa0\xa0The Subcommittee noted an observational cohort study (audit) in Scotland of 2,598 surgical patients admitted with primary hyperparathyroidism (causes of secondary hyperparathyroidism being excluded) between 1986 to 2010 with data followed up until 2011 and including post-surgery outcomes for those who received parathyroidectomy (Collier et al. Endocr Pract. 2019;25:335-9). The Subcommittee noted that 78% of patients included were female, which the Subcommittee considered was a reasonable estimate of female prevalence in this disease.\xa0</p><p><br></p><p>1.7.1.1.\xa0\xa0\xa0The Subcommittee noted that after follow-up, 41% of the total cohort were deceased and the standardised mortality ratio compared with the general population was 1.58, but that 42% of patients did not have surgery (either they did not meet criteria, or for other reasons), and therefore considered this group was more conservatively treated group than those in New Zealand.\xa0</p><p><br></p><p>1.7.1.2.\xa0\xa0\xa0The Subcommittee noted that the raw standardised mortality ratio compared to the general population was 1.30 in patients who received surgery (58% of the cohort) and was 1.88 in patients who were treated conservatively; after adjustment for comorbidity, the latter reduced to 1.49 (95% CI: 1.30 to 1.70; P&lt;.0001). The Subcommittee considered the conservatively treated group was similar to the target New Zealand population for this indication. Based on this, the Subcommittee considered that hyperparathyroidism increases mortality compared with the general population; that surgery can reduce this mortality; and therefore, that it was reasonable to infer that cinacalcet may provide the same or similar benefit as surgery by reducing mortality by reducing serum calcium levels.</p><p><br></p><p>1.7.2.\xa0\xa0\xa0\xa0The Subcommittee was made aware of a systematic review and meta regression of cinacalcet in primary hyperparathyroidism (Ng et al. Endocr Connect. 2020;9:724-35) which included eight trials, none of which the Subcommittee considered provided new information as all had been considered by PTAC or PTAC Subcommittees previously. The Subcommittee noted that 90% of patients had normalisation of calcium levels and 10% had normalisation of parathyroid hormone, however, no other endpoints (eg quality of life) or outcomes for mortality and morbidity were discussed in the publication.\xa0</p><p><br></p><p>1.7.3.\xa0\xa0\xa0\xa0The Subcommittee was made aware of an 8-year retrospective observational cohort study in Scotland of 611 patients with primary hyperparathyroidism seen in secondary care between 2006 and 2014, of which 337 patients did not receive surgery (Reid et al. J Clin Endocrinol Metab. 2019;104:3692-700). The Subcommittee noted that after an 8-year period of follow-up, the mortality rate was 16.0% (98/611) overall, with about 30% of deaths due to cancer and about 30% due to cardiovascular disease. The Subcommittee noted that 79 deaths were reported in the group who did not receive surgery. The Subcommittee noted associations between mortality and increasing age, social deprivation, and elevated adjusted calcium levels at diagnosis that were statistically significant, but no associations with parathyroid hormone levels at diagnosis. The Subcommittee considered that the study population was similar to the target New Zealand population for this indication and was the most representative evidence for the target New Zealand population. The Subcommittee considered it may not be feasible to do an appropriately powered intervention study in this population.\xa0</p><p><br></p><p>1.7.4.\xa0\xa0\xa0\xa0The Subcommittee noted an observational cohort study derived from a random population sample of 750 50-year-old men in Sweden that described a 21 year follow up of men with primary hyperparathyroidism, and which did not show evidence for long term complications nor a mortality difference. The Subcommittee noted this study reported very wide confidence intervals (Kontogeorgos et al. Scand J Clin Lab Invest. 2020;80:6-13).\xa0</p><p><br></p><p>1.8.\xa0\xa0\xa0\xa0The Subcommittee noted that UpToDate suggests cinacalcet be used for patients with symptomatic primary hyperparathyroidism who are unable to have surgery (whose primary indication for surgery is symptomatic and/or severe hypercalcemia), and that cinacalcet would be more appropriate than bisphosphonates where bone density is normal, as supported by literature review updated in April 2021.\xa0</p><p><br></p><p>1.9.\xa0\xa0\xa0\xa0The Subcommittee noted that the previously mentioned NICE guidelines for primary hyperparathyroidism in the UK and Wales (NICE, 2019) recommend cinacalcet be used for patients in whom surgery fails or is denied, to treat symptomatic patients with calcium over 2.85 mmol/L and patients with calcium levels of &gt;3.0 mmol/L with or without symptoms. Members noted that the NICE guidelines state that bisphosphonates should not be used for chronic hypercalcaemia of primary hyperparathyroidism.</p><p><br></p><p>1.10.\xa0\xa0\xa0The Subcommittee considered that there is evidence of improved mortality from secondary hyperparathyroidism in patients on renal dialysis in particular, and that this comorbid population experiences high event rates and pathology-related mortality from hypercalcaemia and secondary hyperparathyroidism, due to the toxicity of the parathyroid hormone.\xa0</p><p><br></p><p>1.11.\xa0\xa0\xa0Overall, the Subcommittee considered that existing evidence for efficacy of cinacalcet in reducing serum calcium in primary hyperparathyroidism is robust. The Subcommittee considered the health benefit for hypercalcaemia is based on biochemical and end-organ endpoints after surgery (which the Subcommittee considered provides strong evidence), and that there is a lack of evidence for reduced mortality in the population with primary hypercalcaemia following treatment with cinacalcet.</p><p><br></p><p>1.12.\xa0\xa0\xa0The Subcommittee considered that there was no new evidence of biochemical efficacy of cinacalcet in reducing serum calcium, although existing evidence for this is robust and that there was strong evidence for cinacalcet compared with surgery in normalising calcium levels (but not in reducing parathyroid hormone levels).\xa0</p><p><br></p><p>Summary</p><p><br></p><p>1.13.\xa0\xa0\xa0The Subcommittee considered that a reduction in calcium to less than 3.0 mmol/L was clinically meaningful and a critical outcome for the target group of patients with primary hyperparathyroidism, whereas that a reduction in parathyroid hormone was not the target outcome for this group.\xa0</p><p><br></p><p>1.14.\xa0\xa0\xa0The Subcommittee considered that it was reasonable to infer, based on the evidence of benefits (including reduction in mortality) from calcium level reduction (from surgery and from the use of cinacalcet in several hypercalcaemic states), that cinacalcet could result in clinically meaningful benefits from a calcium level reduction in people with primary hyperparathyroidism who are not deemed operable. The Subcommittee considered that, while there was limited evidence for the effect of cinacalcet on endpoints such as cardiovascular outcomes, fractures and mortality, it was reasonable to assume that a clinically significant reduction in calcium levels would be associated with improvement in these endpoints.</p><p><br></p><p>1.15.\xa0\xa0\xa0The Subcommittee considered it reasonable for cinacalcet to be funded for people with primary hyperparathyroidism with severe hypercalcemia who are not deemed operable, and have no available alternative treatments. Members noted many such patients would experience neurocognitive effects from elevated calcium. The Subcommittee considered that if funded for this population, cinacalcet would be a chronic intervention to keep calcium low and that, if tolerated and effective in reducing calcium levels, treatment with cinacalcet could be lifelong, or otherwise treatment would be discontinued.\xa0</p><p><br></p><p>1.16.\xa0\xa0\xa0The Subcommittee noted that there was a lack of evidence to inform the frequency and management of interventions to manage acute symptomatic hypercalcaemia, which would incur clinical costs for close observation, monitoring and short-term management. The Subcommittee considered that data regarding quality of life, long-term complications and hospitalisations is not available within the published clinical trial evidence and would need to be obtained from authoritative guidelines and clinician advice.\xa0</p><p><br></p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, if criteria were to be applied to target funding of cinacalcet to this population with primary hyperparathyroidism, all the following would need to be incorporated: hypercalcaemia of &gt;3 mmol/L with or without symptoms, or &gt;2.85 mmol/L with symptoms; the patient is not deemed operable, or surgery has failed or is contraindicated; and the patient has other comorbidities, severe bone pain, or calciphylaxis.</p>', 'Status_History__c': 'a132P000000D5bZQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: rgb(0, 0, 0);"">\ufeff</span>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for primary hyperparathyroidism be funded with a <b>medium priority </b>subject<b> </b>to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application - (primary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Applications valid without further renewal for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has primary hyperparathyroidism; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has hypercalcaemia of &gt;3 mmol/L with or without symptoms; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has hypercalcaemia of &gt;2.85 mmol/L with symptoms; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is not deemed operable, or surgery has failed, or surgery is contraindicated; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has other comorbidities, severe bone pain, or calciphylaxis.</span></p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of people with hypercalcaemia with or without symptoms who are not candidates for surgery and the lack of available treatments for this patient group</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That there remained concerns regarding the indirect evidence of benefit from cinacalcet that uses surrogate outcome measures, but that a reduction in serum calcium from cinacalcet should translate into a reduction in hospitalisations (for treatment of symptomatic hypercalcaemia and its complications) and an improvement in quality of life</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The uncertainty around patient numbers for the target group</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for secondary hyperparathyroidism be funded with a <b>medium priority</b> subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET </b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has tertiary hyperparathyroidism and markedly elevated PTH with hypercalcaemia; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patients has symptomatic secondary hyperparathyroidism with elevated PTH; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is on renal replacement therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has undergone repeated unsuccessful parathyroid exploration with inability to localise residual parathyroid tissue; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid tissue is surgically inaccessible; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid surgery is not feasible and cinacalcet treatment is to be used as a bridge to kidney transplantation.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Following initial treatment with cinacalcet, the patient has had a cinacalcet treatment-free interval of at least 12 weeks; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Cinacalcet is indicated after reassessment of parathyroid function performed at least 6 months after cinacalcet cessation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">\xa0A trial of withdrawal of cinacalcet is clinically inappropriate.</span></p><p>1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence consistent with improved mortality from treatment with cinacalcet from a good quality cohort study</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of strong evidence for quality-of-life benefits from cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of Māori and Pacific peoples with secondary hyperparathyroidism on dialysis who experience health inequities arising from increased incidence of kidney disease and low kidney transplant rates</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The added benefit of another medicine for management of calcium and phosphate in this patient population</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for tertiary hyperparathyroidism be funded with a <b>medium priority</b> subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET </b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has tertiary hyperparathyroidism and markedly elevated PTH with hypercalcaemia; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patients has symptomatic secondary hyperparathyroidism, elevated PTH; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is on renal replacement therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has undergone repeated unsuccessful parathyroid exploration with inability to localise residual parathyroid tissue; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid tissue is surgically inaccessible; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid surgery is not feasible and cinacalcet treatment is to be used as a bridge to kidney transplantation.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Following initial treatment with cinacalcet, the patient has had a cinacalcet treatment-free interval of at least 12 weeks; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Cinacalcet is indicated after reassessment of parathyroid function performed at least 6 months after cinacalcet cessation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">\xa0A trial of withdrawal of cinacalcet is clinically inappropriate.</span></p><p>1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The indirect evidence consistent with improved mortality</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of strong evidence for quality-of-life benefits from cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The added benefit of another medicine for management of calcium and phosphate in this patient population.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that Pharmac should seek advice from the Nephrology Subcommittee regarding the Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism, and considered that the Nephrology Subcommittee’s view on the proposed renewal criteria for patients who may benefit from cinacalcet retreatment following a period off cinacalcet treatment, where appropriate, would be valuable.</p>', 'fs': '<p><span style=""color: rgb(0, 0, 0);"">\ufeff</span>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for primary hyperparathyroidism be funded with a <b>medium priority </b>subject<b> </b>to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application - (primary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Applications valid without further renewal for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has primary hyperparathyroidism; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has hypercalcaemia of &gt;3 mmol/L with or without symptoms; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has hypercalcaemia of &gt;2.85 mmol/L with symptoms; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is not deemed operable, or surgery has failed, or surgery is contraindicated; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has other comorbidities, severe bone pain, or calciphylaxis.</span></p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of people with hypercalcaemia with or without symptoms who are not candidates for surgery and the lack of available treatments for this patient group</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That there remained concerns regarding the indirect evidence of benefit from cinacalcet that uses surrogate outcome measures, but that a reduction in serum calcium from cinacalcet should translate into a reduction in hospitalisations (for treatment of symptomatic hypercalcaemia and its complications) and an improvement in quality of life</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The uncertainty around patient numbers for the target group</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for secondary hyperparathyroidism be funded with a <b>medium priority</b> subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET </b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has tertiary hyperparathyroidism and markedly elevated PTH with hypercalcaemia; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patients has symptomatic secondary hyperparathyroidism with elevated PTH; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is on renal replacement therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has undergone repeated unsuccessful parathyroid exploration with inability to localise residual parathyroid tissue; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid tissue is surgically inaccessible; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid surgery is not feasible and cinacalcet treatment is to be used as a bridge to kidney transplantation.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Following initial treatment with cinacalcet, the patient has had a cinacalcet treatment-free interval of at least 12 weeks; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Cinacalcet is indicated after reassessment of parathyroid function performed at least 6 months after cinacalcet cessation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">\xa0A trial of withdrawal of cinacalcet is clinically inappropriate.</span></p><p>1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence consistent with improved mortality from treatment with cinacalcet from a good quality cohort study</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of strong evidence for quality-of-life benefits from cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of Māori and Pacific peoples with secondary hyperparathyroidism on dialysis who experience health inequities arising from increased incidence of kidney disease and low kidney transplant rates</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The added benefit of another medicine for management of calcium and phosphate in this patient population</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for tertiary hyperparathyroidism be funded with a <b>medium priority</b> subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET </b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has tertiary hyperparathyroidism and markedly elevated PTH with hypercalcaemia; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patients has symptomatic secondary hyperparathyroidism, elevated PTH; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is on renal replacement therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has undergone repeated unsuccessful parathyroid exploration with inability to localise residual parathyroid tissue; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid tissue is surgically inaccessible; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid surgery is not feasible and cinacalcet treatment is to be used as a bridge to kidney transplantation.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Following initial treatment with cinacalcet, the patient has had a cinacalcet treatment-free interval of at least 12 weeks; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Cinacalcet is indicated after reassessment of parathyroid function performed at least 6 months after cinacalcet cessation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">\xa0A trial of withdrawal of cinacalcet is clinically inappropriate.</span></p><p>1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The indirect evidence consistent with improved mortality</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of strong evidence for quality-of-life benefits from cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The added benefit of another medicine for management of calcium and phosphate in this patient population.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that Pharmac should seek advice from the Nephrology Subcommittee regarding the Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism, and considered that the Nephrology Subcommittee’s view on the proposed renewal criteria for patients who may benefit from cinacalcet retreatment following a period off cinacalcet treatment, where appropriate, would be valuable.</p>', 'change': None}, 'Published_Discussion': {'s': '<p><b>Background</b></p><p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the long history of clinical advice regarding cinacalcet for hyperparathyroidism from the Endocrinology Subcommittee, the Nephrology Subcommittee and PTAC, described on the Pharmac Application Tracker items for <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptsL/p000137"" target=""_blank"">primary hyperparathyroidism</a>, <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puCp/p000744"" target=""_blank"">secondary hyperparathyroidism</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puPm/p000985"" target=""_blank"">tertiary hyperparathyroidism</a>. The Committee noted the following in particular:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf"" target=""_blank"">July 2008</a>, PTAC had recommended that hyperparathyroidism (any cause) be declined for listing in the Pharmaceutical Schedule</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">June 2014</a>, the Endocrinology Subcommittee noted a recommendation from the New Zealand Society of Endocrinology to fund cinacalcet for patients with primary hyperparathyroidism who have significant/symptomatic hypercalcaemia (&gt;3mmol/L) and cannot be treated surgically</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">December 2014</a> the Nephrology Subcommittee\xa0recommended cinacalcet for listing in the Pharmaceutical Schedule for secondary and tertiary hyperparathyroidism with calciphylaxis with a medium priority</p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">In May 2016, cinacalcet was listed on the Pharmaceutical Schedule for </span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/notification-of-decision-to-fund-cinacalcet-sensipar-for-parathyroid-carcinoma-and-calciphylaxis/"" target=""_blank"" style=""font-size: 11pt;"">patients with parathyroid carcinoma and symptomatic calciphylaxis,</a><span style=""font-size: 11pt;""> subject to </span><a href=""https://schedule.pharmac.govt.nz/2021/03/01/SA1618.pdf"" target=""_blank"" style=""font-size: 11pt;"">Special Authority criteria</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">December 2016</a>, the Nephrology Subcommittee reiterated its previous recommendation with regards to proposed Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2018-03.pdf"" target=""_blank"">March 2018</a>, the Nephrology Subcommittee considered that access to cinacalcet should be widened to include patients with hyperparathyroidism and kidney disease subject to clinical criteria</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">March 2021</a>, the Endocrinology Subcommittee considered it was reasonable for cinacalcet to be funded for people with primary hyperparathyroidism with severe hypercalcemia who are not deemed operable, and have no available alternative treatments; that a reduction in calcium to less than 3.0 mmol/L was clinically meaningful and a critical outcome for the target group of patients; and that it was reasonable to infer, based on the evidence of benefits (including reduction in mortality) from calcium level reduction (from surgery and from the use of cinacalcet in several hypercalcaemic states), that cinacalcet could result in clinically meaningful benefits from a calcium level reduction in people with primary hyperparathyroidism who are not deemed operable.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that cinacalcet is a modulator of the calcium sensing receptor. It decreases parathyroid hormone levels by increasing the receptor sensitivity to extracellular calcium. The Committee noted that cinacalcet is approved by Medsafe to treat:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis as adjunctive therapy</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>hypercalcaemia in adult patients with parathyroid carcinoma</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>primary hyperparathyroidism in adult patients for whom parathyroidectomy is not a treatment option.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that cinacalcet has long been included within international treatment guidelines and considered no new primary evidence to be available since past reviews of these proposals by the Subcommittees. The Committee considered that the existing clinical trial evidence had been used extensively in meta-analyses and noted that some new meta-analyses and registry descriptive data had been identified.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that for primary hyperparathyroidism, the estimated number of patients who require hospital care was uncertain and that there was a lack of agreement in the estimates of benefit across outcome measures. The Committee considered similarly that for secondary and tertiary hyperparathyroidism there was also a lack of agreement in the estimates of benefit across outcome measures.</p><p><b>Secondary and tertiary hyperparathyroidism</b></p><p>1.5.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that secondary hyperparathyroidism is characterised by excessively high parathyroid hormone levels as a response to prolonged hypocalcaemia or hyperphosphataemia, often due to renal insufficiency. The Committee noted that tertiary hyperparathyroidism develops from long-standing, uncontrolled secondary hyperparathyroidism despite correction (or attempted correction) of hypercalcaemia and hyperphosphataemia, for example in patients with end-stage renal disease of several years&#39; duration.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that Māori and Pacific peoples with secondary hyperparathyroidism on dialysis have a high health need and experience health inequities arising from increased incidence of kidney disease and low kidney transplant rates. The Committee considered that kidney transplant is an effective treatment for secondary hyperparathyroidism if performed before disease becomes severe and is the preferred treatment option for secondary/tertiary hyperparathyroidism. The Committee noted best supportive care is the current treatment for patients with secondary/tertiary hyperparathyroidism who have had, or are unsuitable for, a kidney transplant. However, the Committee considered that this supportive care is associated with poor outcomes.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0</span>Members noted that cinacalcet therapy for secondary/tertiary hyperparathyroidism has been referred to as ‘medical parathyroidectomy’ due to its therapeutic intent.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that there was little new evidence of relevance available since cinacalcet was last considered for secondary and tertiary hyperparathyroidism by Pharmac’s clinical advisory committees, and noted that previous concerns were around the estimates of benefit across outcome measures.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of the <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340919/"" target=""_blank"">Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline update</a>, which did not recommend cinacalcet in chronic kidney disease but did recommended cinacalcet as initial therapy in patients with secondary hyperparathyroidism on dialysis. The Committee noted that KDIGO 2017 did not specifically recommend cinacalcet for tertiary hyperparathyroidism, and noted that cinacalcet is not Medsafe approved for hyperparathyroidism post-transplant but acknowledged that it is used in this setting. The Committee noted that <a href=""https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-dialysis-patients?search=secondary+hyperparathyroidism&amp;source=search_result&amp;selectedTitle=2%7E135&amp;usage_type=default&amp;display_rank=2"" target=""_blank"">UpToDate (July 2021)</a> did not recommend cinacalcet in chronic kidney disease, however UpToDate did recommend cinacalcet for patients with secondary hyperparathyroidism on dialysis following unsuccessful management of calcium and phosphate levels and does not give advice for tertiary hyperparathyroidism.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a large (n=3,526) inception cohort of patients in Sweden with chronic kidney disease in 2006–2012 (both non-dialysis, dialysis and transplanted) with evidence of secondary hyperparathyroidism who were followed up for median 37 months (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794851/"" target=""_blank"">Evans et al. Sci Rep. 2018;8:2103</a>). The Committee noted that 12% of patients commenced cinacalcet and the authors had reported this treatment was associated with trends towards an all-cause mortality advantage (adjusted odds ratio 0.79; 95%CI: 0.56 to 1.11), ascribed mostly to a reduction in the odds of fatal/non-fatal cardiovascular events (odds ratio 0.67; 95%CI: 0.48 to 0.93).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a randomised, open label study in chronic haemodialysis patients (n=45) with severe secondary hyperparathyroidism that explored the effect of cinacalcet on chronic kidney disease-mineral bone disorder parameters including calcium (<a href=""https://www.tandfonline.com/doi/full/10.1080/0886022X.2018.1562356"" target=""_blank"">Susantitaphong et al. Ren Fail. 2019;41:326-33</a>). The Committee noted the authors reported that cinacalcet was associated with a reduction in parathyroid hormone levels and a benefit in bone mineral markers.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted two meta-analyses that included randomised controlled trial evidence and long-term (up to 7 years) observational data for patients on dialysis, which concluded that cinacalcet reduced all-cause mortality vs placebo in secondary hyperparathyroidism (<span style=""color: black;"">relative risk [RR] 0.91, 95% CI 0.89-0.94, </span><i style=""color: black;"">P</i><span style=""color: black;""> &lt; 0.001; </span><a href=""https://www.karger.com/?DOI=10.1159/000504139"" target=""_blank"">Zu et al. Kidney Blood Press Res. 2019;44:1327-38</a><span style=""color: black;"">; hazard ratio: 0.83; 95% credible interval: 0.78–0.89; </span><a href=""https://www.futuremedicine.com/doi/full/10.2217/cer-2018-0015"" target=""_blank"">Lozano-Ortega et al. J Comp Eff Res. 2018;7:693-707</a><span style=""color: black;"">).</span></p><p>1.13.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a meta-analysis of generally short-term (less than two years’ follow-up) randomised controlled trial evidence in patients with secondary hyperparathyroidism in chronic kidney disease, which reported that cinacalcet administration did not reduce all-cause mortality vs placebo (RR = 0.97, 95% CI = 0.89-1.05, <i>P </i>= 0.41; <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29449603/"" target=""_blank"">Wang et al. Sci Rep. 2018;8:3111</a>). However, members noted that a large proportion of data in the meta-analysis came from one study (EVOLVE) that reported no mortality advantage overall but did report in sub-population analysis a mortality advantage in patients over 60 years of age (<a href=""https://www.nejm.org/doi/full/10.1056/nejmoa1205624#article_letters"" target=""_blank"">The EVOLVE trial Investigators. N Engl J Med 2012;367:2482-94</a><span style=""color: black;"">). The Committee has previously noted various issues with the EVOLVE trial including its post-hoc subgroup analyses (</span><a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC May 2016 record paragraph 8.24</a><span style=""color: black;"">).</span></p><p>1.14.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a systematic review and meta-analysis of long-term mortality after parathyroidectomy or medical treatment from cohort studies including over 20,000 chronic kidney disease patients with secondary hyperparathyroidism, which reported a reduction in all-case death (HR 0.72) and in cardiovascular death (HR 0.63) with surgery (<a href=""https://www.tandfonline.com/doi/full/10.1080/0886022X.2016.1184924"" target=""_blank"">Chen et al. Ren Fail. 2016;38:1050-8</a><span style=""color: black;"">). Members considered the number of patients who received cinacalcet was likely low given the enrolment to the individual trials could have ceased in about 2013 and that the survival benefit </span>reported for surgery over cinacalcet likely underestimated the benefit of cinacalcet as a medical parathyroidectomy.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a meta-analysis of eight randomised controlled trials, which concluded that cinacalcet reduces serum calcium and serum phosphate but not parathyroid hormone parameters in patients with secondary hyperparathyroidism on dialysis and reported no unexpected safety signals with cinacalcet and vitamin D (<a href=""https://doi.org/10.1007/s11255-019-02271-6"" target=""_blank"">Xu et al. Int Urol Nephrol. 2019;51:2027-36</a>). Members noted however that a large proportion of data in the meta-analysis was derived from one study which investigated intravenous treatment with another agent.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of observational evidence from the limited European Dialysis Outcomes and Practice Patterns Study (DOPPS) registry compared with real-world descriptive data which suggested an increase in five-year survival with optimal management across several factors including serum albumin (which was key), phosphate, haemoglobin, vascular access and fluids in a population with\xa0predominantly secondary hyperparathyroidism on dialysis (<a href=""https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1251-z#citeas"" target=""_blank"">Combe et al. BMC Nephrol. 2019;20:81</a>). Members considered cinacalcet may support management of phosphate levels in this setting and that phosphate management was likely associated with a mortality benefit.\xa0</p><p>1.17.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of earlier, observational data from the DOPPS registry reporting that very high and very low parathyroid hormone levels were associated with increased mortality in patients on dialysis (HR for death 1.09; <a href=""https://cjasn.asnjournals.org/cgi/pmidlookup?view=long&amp;pmid=25516917"" target=""_blank"">Tentori et al. Clin J Am Soc Nephrol. 2015;10:98-109).</a></p><p>1.18.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a randomised trial of different surgical approaches to parathyroidectomy. This study reported substantial changes from baseline in the physical and mental component summary scores of the SF-36 that did not differ for the different types of surgery (<a href=""https://www.sciencedirect.com/science/article/abs/pii/S0039606018303763?via%3Dihub"" target=""_blank"">Filho et al. Surgery. 2018;164:978-85</a>). However, the Committee considered that this was not direct evidence for an improvement in quality of life with cinacalcet in secondary (or tertiary) hyperparathyroidism, as cinacalcet was not compared to surgery in that study, and that while cinacalcet may be considered a medical parathyroidectomy, any quality-of-life benefit of cinacalcet would be subject to significant uncertainty.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the meta-analyses in tertiary hyperparathyroidism were of lesser quality due to their cohort study design constituents, although considered that the large Swedish cohort study reported by <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794851/"" target=""_blank"">Evans et al. (Sci Rep. 2018;8:2103</a>) was of good quality.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that a small (n=24) randomised cohort study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism reported normalised serum calcium levels in 7 of 11 patients (64%) in the parathyroidectomy group and 6 of 13 patients (46%) in the cinacalcet group (<i>P</i>=0.44) after five years (<a href=""https://doi.org/10.1111/ctr.13988"" target=""_blank"">Moreno et al. Clin Transplant. 2020;34:e13988</a>). The Committee noted that there were no differences observed in kidney function and the incidence of fragility fractures between both groups.</p><p>1.21. The Committee noted evidence from a single centre, retrospective cohort study of patients with tertiary hyperparathyroidism (<i>N</i>=83, of which 52 received observation alone, 13 received cinacalcet treatment and 18 received parathyroidectomy), and noted that the main determinant of management was the magnitude of elevated serum calcium (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2012/07150/Tertiary_Hyperparathyroidism_in_Kidney_Transplant.11.aspx?casa_token=nB2FUdJc644AAAAA:p7QDHuZg4iSkBQ8RSbnRlJE6mZ9BDOOMmQ_9CHwmqqzwoDmpqnr2jGNoWdNMKTGh6eCOwOGMFPpBMwkk3YjXSFA"" target=""_blank"">Yang et al. Transplantation 2012;15: 70-6</a>). The Committee noted evidence that reported 38% of transplanted patients had elevated parathyroid hormone levels 9-12 months post-transplant; and of these, 63% were observed and the remainder received cinacalcet with or without surgery (<a href=""https://www.sciencedirect.com/science/article/abs/pii/S0039606015007357?casa_token=5GIVcUD3zjAAAAAA:x4oTW8S9LkoDmLTTV7_ANwcB2Y-7-z3I4eWziQ_2CjNbuwrf1WeoyVRI6PG0f9cuIP7aShwK#bib1"" target=""_blank"">Lou et al. Surgery 2016;159: 172-80</a>). The Committee considered that this evidence suggests half of this patient group could be managed without an intervention.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the evidence for tertiary hyperparathyroidism from small cohort studies added little to the evidence for cinacalcet in this setting.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0</span>Overall, the Committee noted that there was no direct evidence of a mortality benefit from cinacalcet in secondary or tertiary hyperparathyroidism although there was indirect evidence of an association between reduced calcium levels and mortality. The Committee considered that outcomes associated with cinacalcet therapy were good relative to surgical outcomes and that this supported the concept of a mortality benefit from cinacalcet. The Committee considered that a mortality benefit was likely the most plausible outcome for patients with secondary hyperparathyroidism receiving cinacalcet. Members considered that cinacalcet may improve allograft survival post kidney transplant in patients with tertiary hyperparathyroidism, although there was an absence of new data to support this.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the side effect profile of cinacalcet is well recognised with 10-30% of patients experiencing gastrointestinal upset that may lead to discontinuation.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet could appropriately form part of the treatment approach for patients with secondary and tertiary hyperparathyroidism who are on dialysis, used as an extra therapy alongside existing treatments in the paradigm for a multi-modal approach to disease management. The Committee considered that serum calcium and phosphate levels are difficult to manage with currently available treatments, and that cinacalcet may make these easier to manage for patients with chronic kidney disease, with particular impact in the management of patients with secondary hyperparathyroidism.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that, if cinacalcet was funded for secondary hyperparathyroidism, there may be a desire to access it prior to parathyroidectomy especially in patients who were seeking parathyroidectomy while awaiting a kidney transplant. The Committee considered that concerns regarding general anaesthesia may preclude parathyroid surgery as an option for some patients. The Committee considered that a small group may seek cinacalcet access post-surgery and that some patients may access cinacalcet prior to kidney transplant.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet treatment would be ongoing for those deemed to be requiring it and receiving benefit from it, however, members noted that cinacalcet may not be needed long-term in patients with tertiary hyperparathyroidism whose elevated parathyroid hormone levels resolve post-transplant. The Committee considered parathyroid hormone levels would resolve post-transplant in about two-thirds of cases. The Committee considered it would be reasonable for cinacalcet to be subject to renewal criteria requiring assessment after a period off treatment to confirm the need for further cinacalcet treatment and appropriately target the intended population. The Committee considered that Pharmac should seek advice from the Nephrology Subcommittee regarding the Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism, and considered that the Subcommittee’s view on the proposed renewal criteria for patients who may benefit from cinacalcet retreatment following a period off cinacalcet treatment, where appropriate, would be valuable.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the Nephrology Subcommittee in 2014 had estimated that approximately 5% of dialysis patients would be eligible for cinacalcet treatment under the proposed criteria. The Committee considered these were likely to be an underestimate, and that it is possible over 50% of patients on dialysis may fit the proposed Special Authority criteria. The Committee considered that based on the surgery criteria in the proposed Special Authority criteria, cinacalcet may plausibly be used prior to surgery in some patients. The Committee considered that many of those that would benefit from cinacalcet in this setting would be Māori and Pacific peoples.</p><p>1.29.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted Pharmac staff’s estimate of patient numbers for tertiary hyperparathyroidism, which assumed approximately 17% of patients developed tertiary hyperparathyroidism after renal transplant (<a href=""https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.12911"" target=""_blank"">Evenepoel et al. Am J Transplant 2014;14: 2545-55</a>). The Committee considered it was uncertain what proportion of these patients would meet the proposed criteria for cinacalcet and therefore receive treatment, but that an estimate of 25% of these patients requiring cinacalcet was reasonable. The Committee considered that tertiary hyperparathyroidism would resolve itself within 12 months in a proportion of patients, and that the time on treatment would therefore be quite short for some patients.</p><p>1.30.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet may reduce the number of hospitalisations in patients with secondary and tertiary hyperparathyroidism, but any hospitalisation reduction would likely be small. The Committee considered it was plausible that cinacalcet may provide no additional quality-of-life benefits compared with standard of care in the setting of secondary hyperparathyroidism, noting the complex care required for this comorbid patient population. However, the Committee considered that any quality of life benefits would be valuable to patients on renal replacement therapy.</p><p>1.31.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for cinacalcet if it were to be funded in New Zealand for secondary hyperparathyroidism. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><table class=""ql-table-blob"" border=""0"" style=""width: 460.45pt;"" width=""614""><tbody><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal""><b>P</b><span style=""color: black;"">opulation </span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Patients on dialysis with symptomatic\n  secondary hyperparathyroidism and elevated PTH who are unable to receive\n  surgical treatment. </p></td></tr><tr style=""height: 17.65pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 17.65pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">I</span></b><span style=""color: black;"">ntervention</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 17.65pt;"" width=""514""><p class=""MsoNormal"" style="""">Cinacalcet, mean daily dose of 60 mg,\n  based on Nephrology Subcommittee advice in 2014</p></td></tr><tr style=""height: 3.4pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 3.4pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">C</span></b><span style=""color: black;"">omparator(s)</span></p><p class=""MsoNormal""><span style=""color: black;"">(NZ context)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 3.4pt;"" width=""514""><p class=""MsoNormal"" style="""">Best supportive care </p></td></tr><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">O</span></b><span style=""color: black;"">utcome(s)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Significant reduction in serum calcium and\n  serum phosphate</p><p class=""MsoNormal"" style="""">Probable but poorly-defined benefit on\n  mortality (most likely outcome), cardiovascular events and health-related\n  quality of life </p><p class=""MsoNormal"">Very small reduction in the need for hospitalisations to\n  correct hypercalcaemia</p><p class=""MsoNormal"">\xa0</p><p class=""MsoNormal"">Improved phosphate management, which may be associated\n  with mortality benefits </p></td></tr></tbody></table><p><br></p>', 'fs': '<p><b>Background</b></p><p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the long history of clinical advice regarding cinacalcet for hyperparathyroidism from the Endocrinology Subcommittee, the Nephrology Subcommittee and PTAC, described on the Pharmac Application Tracker items for <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptsL/p000137"" target=""_blank"">primary hyperparathyroidism</a>, <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puCp/p000744"" target=""_blank"">secondary hyperparathyroidism</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puPm/p000985"" target=""_blank"">tertiary hyperparathyroidism</a>. The Committee noted the following in particular:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf"" target=""_blank"">July 2008</a>, PTAC had recommended that hyperparathyroidism (any cause) be declined for listing in the Pharmaceutical Schedule</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">June 2014</a>, the Endocrinology Subcommittee noted a recommendation from the New Zealand Society of Endocrinology to fund cinacalcet for patients with primary hyperparathyroidism who have significant/symptomatic hypercalcaemia (&gt;3mmol/L) and cannot be treated surgically</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">December 2014</a> the Nephrology Subcommittee\xa0recommended cinacalcet for listing in the Pharmaceutical Schedule for secondary and tertiary hyperparathyroidism with calciphylaxis with a medium priority</p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">In May 2016, cinacalcet was listed on the Pharmaceutical Schedule for </span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/notification-of-decision-to-fund-cinacalcet-sensipar-for-parathyroid-carcinoma-and-calciphylaxis/"" target=""_blank"" style=""font-size: 11pt;"">patients with parathyroid carcinoma and symptomatic calciphylaxis,</a><span style=""font-size: 11pt;""> subject to </span><a href=""https://schedule.pharmac.govt.nz/2021/03/01/SA1618.pdf"" target=""_blank"" style=""font-size: 11pt;"">Special Authority criteria</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">December 2016</a>, the Nephrology Subcommittee reiterated its previous recommendation with regards to proposed Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2018-03.pdf"" target=""_blank"">March 2018</a>, the Nephrology Subcommittee considered that access to cinacalcet should be widened to include patients with hyperparathyroidism and kidney disease subject to clinical criteria</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">March 2021</a>, the Endocrinology Subcommittee considered it was reasonable for cinacalcet to be funded for people with primary hyperparathyroidism with severe hypercalcemia who are not deemed operable, and have no available alternative treatments; that a reduction in calcium to less than 3.0 mmol/L was clinically meaningful and a critical outcome for the target group of patients; and that it was reasonable to infer, based on the evidence of benefits (including reduction in mortality) from calcium level reduction (from surgery and from the use of cinacalcet in several hypercalcaemic states), that cinacalcet could result in clinically meaningful benefits from a calcium level reduction in people with primary hyperparathyroidism who are not deemed operable.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that cinacalcet is a modulator of the calcium sensing receptor. It decreases parathyroid hormone levels by increasing the receptor sensitivity to extracellular calcium. The Committee noted that cinacalcet is approved by Medsafe to treat:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis as adjunctive therapy</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>hypercalcaemia in adult patients with parathyroid carcinoma</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>primary hyperparathyroidism in adult patients for whom parathyroidectomy is not a treatment option.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that cinacalcet has long been included within international treatment guidelines and considered no new primary evidence to be available since past reviews of these proposals by the Subcommittees. The Committee considered that the existing clinical trial evidence had been used extensively in meta-analyses and noted that some new meta-analyses and registry descriptive data had been identified.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that for primary hyperparathyroidism, the estimated number of patients who require hospital care was uncertain and that there was a lack of agreement in the estimates of benefit across outcome measures. The Committee considered similarly that for secondary and tertiary hyperparathyroidism there was also a lack of agreement in the estimates of benefit across outcome measures.</p><p><b>Secondary and tertiary hyperparathyroidism</b></p><p>1.5.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that secondary hyperparathyroidism is characterised by excessively high parathyroid hormone levels as a response to prolonged hypocalcaemia or hyperphosphataemia, often due to renal insufficiency. The Committee noted that tertiary hyperparathyroidism develops from long-standing, uncontrolled secondary hyperparathyroidism despite correction (or attempted correction) of hypercalcaemia and hyperphosphataemia, for example in patients with end-stage renal disease of several years&#39; duration.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that Māori and Pacific peoples with secondary hyperparathyroidism on dialysis have a high health need and experience health inequities arising from increased incidence of kidney disease and low kidney transplant rates. The Committee considered that kidney transplant is an effective treatment for secondary hyperparathyroidism if performed before disease becomes severe and is the preferred treatment option for secondary/tertiary hyperparathyroidism. The Committee noted best supportive care is the current treatment for patients with secondary/tertiary hyperparathyroidism who have had, or are unsuitable for, a kidney transplant. However, the Committee considered that this supportive care is associated with poor outcomes.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0</span>Members noted that cinacalcet therapy for secondary/tertiary hyperparathyroidism has been referred to as ‘medical parathyroidectomy’ due to its therapeutic intent.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that there was little new evidence of relevance available since cinacalcet was last considered for secondary and tertiary hyperparathyroidism by Pharmac’s clinical advisory committees, and noted that previous concerns were around the estimates of benefit across outcome measures.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of the <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340919/"" target=""_blank"">Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline update</a>, which did not recommend cinacalcet in chronic kidney disease but did recommended cinacalcet as initial therapy in patients with secondary hyperparathyroidism on dialysis. The Committee noted that KDIGO 2017 did not specifically recommend cinacalcet for tertiary hyperparathyroidism, and noted that cinacalcet is not Medsafe approved for hyperparathyroidism post-transplant but acknowledged that it is used in this setting. The Committee noted that <a href=""https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-dialysis-patients?search=secondary+hyperparathyroidism&amp;source=search_result&amp;selectedTitle=2%7E135&amp;usage_type=default&amp;display_rank=2"" target=""_blank"">UpToDate (July 2021)</a> did not recommend cinacalcet in chronic kidney disease, however UpToDate did recommend cinacalcet for patients with secondary hyperparathyroidism on dialysis following unsuccessful management of calcium and phosphate levels and does not give advice for tertiary hyperparathyroidism.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a large (n=3,526) inception cohort of patients in Sweden with chronic kidney disease in 2006–2012 (both non-dialysis, dialysis and transplanted) with evidence of secondary hyperparathyroidism who were followed up for median 37 months (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794851/"" target=""_blank"">Evans et al. Sci Rep. 2018;8:2103</a>). The Committee noted that 12% of patients commenced cinacalcet and the authors had reported this treatment was associated with trends towards an all-cause mortality advantage (adjusted odds ratio 0.79; 95%CI: 0.56 to 1.11), ascribed mostly to a reduction in the odds of fatal/non-fatal cardiovascular events (odds ratio 0.67; 95%CI: 0.48 to 0.93).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a randomised, open label study in chronic haemodialysis patients (n=45) with severe secondary hyperparathyroidism that explored the effect of cinacalcet on chronic kidney disease-mineral bone disorder parameters including calcium (<a href=""https://www.tandfonline.com/doi/full/10.1080/0886022X.2018.1562356"" target=""_blank"">Susantitaphong et al. Ren Fail. 2019;41:326-33</a>). The Committee noted the authors reported that cinacalcet was associated with a reduction in parathyroid hormone levels and a benefit in bone mineral markers.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted two meta-analyses that included randomised controlled trial evidence and long-term (up to 7 years) observational data for patients on dialysis, which concluded that cinacalcet reduced all-cause mortality vs placebo in secondary hyperparathyroidism (<span style=""color: black;"">relative risk [RR] 0.91, 95% CI 0.89-0.94, </span><i style=""color: black;"">P</i><span style=""color: black;""> &lt; 0.001; </span><a href=""https://www.karger.com/?DOI=10.1159/000504139"" target=""_blank"">Zu et al. Kidney Blood Press Res. 2019;44:1327-38</a><span style=""color: black;"">; hazard ratio: 0.83; 95% credible interval: 0.78–0.89; </span><a href=""https://www.futuremedicine.com/doi/full/10.2217/cer-2018-0015"" target=""_blank"">Lozano-Ortega et al. J Comp Eff Res. 2018;7:693-707</a><span style=""color: black;"">).</span></p><p>1.13.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a meta-analysis of generally short-term (less than two years’ follow-up) randomised controlled trial evidence in patients with secondary hyperparathyroidism in chronic kidney disease, which reported that cinacalcet administration did not reduce all-cause mortality vs placebo (RR = 0.97, 95% CI = 0.89-1.05, <i>P </i>= 0.41; <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29449603/"" target=""_blank"">Wang et al. Sci Rep. 2018;8:3111</a>). However, members noted that a large proportion of data in the meta-analysis came from one study (EVOLVE) that reported no mortality advantage overall but did report in sub-population analysis a mortality advantage in patients over 60 years of age (<a href=""https://www.nejm.org/doi/full/10.1056/nejmoa1205624#article_letters"" target=""_blank"">The EVOLVE trial Investigators. N Engl J Med 2012;367:2482-94</a><span style=""color: black;"">). The Committee has previously noted various issues with the EVOLVE trial including its post-hoc subgroup analyses (</span><a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC May 2016 record paragraph 8.24</a><span style=""color: black;"">).</span></p><p>1.14.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a systematic review and meta-analysis of long-term mortality after parathyroidectomy or medical treatment from cohort studies including over 20,000 chronic kidney disease patients with secondary hyperparathyroidism, which reported a reduction in all-case death (HR 0.72) and in cardiovascular death (HR 0.63) with surgery (<a href=""https://www.tandfonline.com/doi/full/10.1080/0886022X.2016.1184924"" target=""_blank"">Chen et al. Ren Fail. 2016;38:1050-8</a><span style=""color: black;"">). Members considered the number of patients who received cinacalcet was likely low given the enrolment to the individual trials could have ceased in about 2013 and that the survival benefit </span>reported for surgery over cinacalcet likely underestimated the benefit of cinacalcet as a medical parathyroidectomy.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a meta-analysis of eight randomised controlled trials, which concluded that cinacalcet reduces serum calcium and serum phosphate but not parathyroid hormone parameters in patients with secondary hyperparathyroidism on dialysis and reported no unexpected safety signals with cinacalcet and vitamin D (<a href=""https://doi.org/10.1007/s11255-019-02271-6"" target=""_blank"">Xu et al. Int Urol Nephrol. 2019;51:2027-36</a>). Members noted however that a large proportion of data in the meta-analysis was derived from one study which investigated intravenous treatment with another agent.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of observational evidence from the limited European Dialysis Outcomes and Practice Patterns Study (DOPPS) registry compared with real-world descriptive data which suggested an increase in five-year survival with optimal management across several factors including serum albumin (which was key), phosphate, haemoglobin, vascular access and fluids in a population with\xa0predominantly secondary hyperparathyroidism on dialysis (<a href=""https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1251-z#citeas"" target=""_blank"">Combe et al. BMC Nephrol. 2019;20:81</a>). Members considered cinacalcet may support management of phosphate levels in this setting and that phosphate management was likely associated with a mortality benefit.\xa0</p><p>1.17.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of earlier, observational data from the DOPPS registry reporting that very high and very low parathyroid hormone levels were associated with increased mortality in patients on dialysis (HR for death 1.09; <a href=""https://cjasn.asnjournals.org/cgi/pmidlookup?view=long&amp;pmid=25516917"" target=""_blank"">Tentori et al. Clin J Am Soc Nephrol. 2015;10:98-109).</a></p><p>1.18.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a randomised trial of different surgical approaches to parathyroidectomy. This study reported substantial changes from baseline in the physical and mental component summary scores of the SF-36 that did not differ for the different types of surgery (<a href=""https://www.sciencedirect.com/science/article/abs/pii/S0039606018303763?via%3Dihub"" target=""_blank"">Filho et al. Surgery. 2018;164:978-85</a>). However, the Committee considered that this was not direct evidence for an improvement in quality of life with cinacalcet in secondary (or tertiary) hyperparathyroidism, as cinacalcet was not compared to surgery in that study, and that while cinacalcet may be considered a medical parathyroidectomy, any quality-of-life benefit of cinacalcet would be subject to significant uncertainty.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the meta-analyses in tertiary hyperparathyroidism were of lesser quality due to their cohort study design constituents, although considered that the large Swedish cohort study reported by <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794851/"" target=""_blank"">Evans et al. (Sci Rep. 2018;8:2103</a>) was of good quality.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that a small (n=24) randomised cohort study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism reported normalised serum calcium levels in 7 of 11 patients (64%) in the parathyroidectomy group and 6 of 13 patients (46%) in the cinacalcet group (<i>P</i>=0.44) after five years (<a href=""https://doi.org/10.1111/ctr.13988"" target=""_blank"">Moreno et al. Clin Transplant. 2020;34:e13988</a>). The Committee noted that there were no differences observed in kidney function and the incidence of fragility fractures between both groups.</p><p>1.21. The Committee noted evidence from a single centre, retrospective cohort study of patients with tertiary hyperparathyroidism (<i>N</i>=83, of which 52 received observation alone, 13 received cinacalcet treatment and 18 received parathyroidectomy), and noted that the main determinant of management was the magnitude of elevated serum calcium (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2012/07150/Tertiary_Hyperparathyroidism_in_Kidney_Transplant.11.aspx?casa_token=nB2FUdJc644AAAAA:p7QDHuZg4iSkBQ8RSbnRlJE6mZ9BDOOMmQ_9CHwmqqzwoDmpqnr2jGNoWdNMKTGh6eCOwOGMFPpBMwkk3YjXSFA"" target=""_blank"">Yang et al. Transplantation 2012;15: 70-6</a>). The Committee noted evidence that reported 38% of transplanted patients had elevated parathyroid hormone levels 9-12 months post-transplant; and of these, 63% were observed and the remainder received cinacalcet with or without surgery (<a href=""https://www.sciencedirect.com/science/article/abs/pii/S0039606015007357?casa_token=5GIVcUD3zjAAAAAA:x4oTW8S9LkoDmLTTV7_ANwcB2Y-7-z3I4eWziQ_2CjNbuwrf1WeoyVRI6PG0f9cuIP7aShwK#bib1"" target=""_blank"">Lou et al. Surgery 2016;159: 172-80</a>). The Committee considered that this evidence suggests half of this patient group could be managed without an intervention.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the evidence for tertiary hyperparathyroidism from small cohort studies added little to the evidence for cinacalcet in this setting.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0</span>Overall, the Committee noted that there was no direct evidence of a mortality benefit from cinacalcet in secondary or tertiary hyperparathyroidism although there was indirect evidence of an association between reduced calcium levels and mortality. The Committee considered that outcomes associated with cinacalcet therapy were good relative to surgical outcomes and that this supported the concept of a mortality benefit from cinacalcet. The Committee considered that a mortality benefit was likely the most plausible outcome for patients with secondary hyperparathyroidism receiving cinacalcet. Members considered that cinacalcet may improve allograft survival post kidney transplant in patients with tertiary hyperparathyroidism, although there was an absence of new data to support this.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the side effect profile of cinacalcet is well recognised with 10-30% of patients experiencing gastrointestinal upset that may lead to discontinuation.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet could appropriately form part of the treatment approach for patients with secondary and tertiary hyperparathyroidism who are on dialysis, used as an extra therapy alongside existing treatments in the paradigm for a multi-modal approach to disease management. The Committee considered that serum calcium and phosphate levels are difficult to manage with currently available treatments, and that cinacalcet may make these easier to manage for patients with chronic kidney disease, with particular impact in the management of patients with secondary hyperparathyroidism.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that, if cinacalcet was funded for secondary hyperparathyroidism, there may be a desire to access it prior to parathyroidectomy especially in patients who were seeking parathyroidectomy while awaiting a kidney transplant. The Committee considered that concerns regarding general anaesthesia may preclude parathyroid surgery as an option for some patients. The Committee considered that a small group may seek cinacalcet access post-surgery and that some patients may access cinacalcet prior to kidney transplant.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet treatment would be ongoing for those deemed to be requiring it and receiving benefit from it, however, members noted that cinacalcet may not be needed long-term in patients with tertiary hyperparathyroidism whose elevated parathyroid hormone levels resolve post-transplant. The Committee considered parathyroid hormone levels would resolve post-transplant in about two-thirds of cases. The Committee considered it would be reasonable for cinacalcet to be subject to renewal criteria requiring assessment after a period off treatment to confirm the need for further cinacalcet treatment and appropriately target the intended population. The Committee considered that Pharmac should seek advice from the Nephrology Subcommittee regarding the Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism, and considered that the Subcommittee’s view on the proposed renewal criteria for patients who may benefit from cinacalcet retreatment following a period off cinacalcet treatment, where appropriate, would be valuable.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the Nephrology Subcommittee in 2014 had estimated that approximately 5% of dialysis patients would be eligible for cinacalcet treatment under the proposed criteria. The Committee considered these were likely to be an underestimate, and that it is possible over 50% of patients on dialysis may fit the proposed Special Authority criteria. The Committee considered that based on the surgery criteria in the proposed Special Authority criteria, cinacalcet may plausibly be used prior to surgery in some patients. The Committee considered that many of those that would benefit from cinacalcet in this setting would be Māori and Pacific peoples.</p><p>1.29.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted Pharmac staff’s estimate of patient numbers for tertiary hyperparathyroidism, which assumed approximately 17% of patients developed tertiary hyperparathyroidism after renal transplant (<a href=""https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.12911"" target=""_blank"">Evenepoel et al. Am J Transplant 2014;14: 2545-55</a>). The Committee considered it was uncertain what proportion of these patients would meet the proposed criteria for cinacalcet and therefore receive treatment, but that an estimate of 25% of these patients requiring cinacalcet was reasonable. The Committee considered that tertiary hyperparathyroidism would resolve itself within 12 months in a proportion of patients, and that the time on treatment would therefore be quite short for some patients.</p><p>1.30.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet may reduce the number of hospitalisations in patients with secondary and tertiary hyperparathyroidism, but any hospitalisation reduction would likely be small. The Committee considered it was plausible that cinacalcet may provide no additional quality-of-life benefits compared with standard of care in the setting of secondary hyperparathyroidism, noting the complex care required for this comorbid patient population. However, the Committee considered that any quality of life benefits would be valuable to patients on renal replacement therapy.</p><p>1.31.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for cinacalcet if it were to be funded in New Zealand for secondary hyperparathyroidism. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><table class=""ql-table-blob"" border=""0"" style=""width: 460.45pt;"" width=""614""><tbody><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal""><b>P</b><span style=""color: black;"">opulation </span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Patients on dialysis with symptomatic\n  secondary hyperparathyroidism and elevated PTH who are unable to receive\n  surgical treatment. </p></td></tr><tr style=""height: 17.65pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 17.65pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">I</span></b><span style=""color: black;"">ntervention</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 17.65pt;"" width=""514""><p class=""MsoNormal"" style="""">Cinacalcet, mean daily dose of 60 mg,\n  based on Nephrology Subcommittee advice in 2014</p></td></tr><tr style=""height: 3.4pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 3.4pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">C</span></b><span style=""color: black;"">omparator(s)</span></p><p class=""MsoNormal""><span style=""color: black;"">(NZ context)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 3.4pt;"" width=""514""><p class=""MsoNormal"" style="""">Best supportive care </p></td></tr><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">O</span></b><span style=""color: black;"">utcome(s)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Significant reduction in serum calcium and\n  serum phosphate</p><p class=""MsoNormal"" style="""">Probable but poorly-defined benefit on\n  mortality (most likely outcome), cardiovascular events and health-related\n  quality of life </p><p class=""MsoNormal"">Very small reduction in the need for hospitalisations to\n  correct hypercalcaemia</p><p class=""MsoNormal"">\xa0</p><p class=""MsoNormal"">Improved phosphate management, which may be associated\n  with mortality benefits </p></td></tr></tbody></table><p><br></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered cinacalcet for primary, secondary and tertiary hyperparathyroidism to support Pharmac’s assessment of these proposals.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered cinacalcet for primary, secondary and tertiary hyperparathyroidism to support Pharmac’s assessment of these proposals.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2021', 'fs': 'Nov 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 20 August 2021.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 20 August 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRiUAI'}, 'Id': 'a0P2P000006pnRiUAI', 'Event_Date__c': '2021-11-23', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 20 August 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Nov 2021', 'Published_Recommendation__c': '<p><span style=""color: rgb(0, 0, 0);"">\ufeff</span>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for primary hyperparathyroidism be funded with a <b>medium priority </b>subject<b> </b>to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET</b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application - (primary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Applications valid without further renewal for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has primary hyperparathyroidism; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has hypercalcaemia of &gt;3 mmol/L with or without symptoms; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has hypercalcaemia of &gt;2.85 mmol/L with symptoms; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is not deemed operable, or surgery has failed, or surgery is contraindicated; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has other comorbidities, severe bone pain, or calciphylaxis.</span></p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of people with hypercalcaemia with or without symptoms who are not candidates for surgery and the lack of available treatments for this patient group</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>That there remained concerns regarding the indirect evidence of benefit from cinacalcet that uses surrogate outcome measures, but that a reduction in serum calcium from cinacalcet should translate into a reduction in hospitalisations (for treatment of symptomatic hypercalcaemia and its complications) and an improvement in quality of life</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The uncertainty around patient numbers for the target group</p><p class=""ql-indent-2""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for secondary hyperparathyroidism be funded with a <b>medium priority</b> subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET </b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has tertiary hyperparathyroidism and markedly elevated PTH with hypercalcaemia; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patients has symptomatic secondary hyperparathyroidism with elevated PTH; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is on renal replacement therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has undergone repeated unsuccessful parathyroid exploration with inability to localise residual parathyroid tissue; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid tissue is surgically inaccessible; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid surgery is not feasible and cinacalcet treatment is to be used as a bridge to kidney transplantation.</span></p><p><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Following initial treatment with cinacalcet, the patient has had a cinacalcet treatment-free interval of at least 12 weeks; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Cinacalcet is indicated after reassessment of parathyroid function performed at least 6 months after cinacalcet cessation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">\xa0A trial of withdrawal of cinacalcet is clinically inappropriate.</span></p><p>1.2.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The evidence consistent with improved mortality from treatment with cinacalcet from a good quality cohort study</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of strong evidence for quality-of-life benefits from cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The high health need of Māori and Pacific peoples with secondary hyperparathyroidism on dialysis who experience health inequities arising from increased incidence of kidney disease and low kidney transplant rates</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The added benefit of another medicine for management of calcium and phosphate in this patient population</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee <b>recommended</b> that cinacalcet for tertiary hyperparathyroidism be funded with a <b>medium priority</b> subject to the following Special Authority criteria:</p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">CINACALCET </b></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Initial application – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All of the following:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has tertiary hyperparathyroidism and markedly elevated PTH with hypercalcaemia; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patients has symptomatic secondary hyperparathyroidism, elevated PTH; and </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is on renal replacement therapy; and</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Any of the following: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Patient has undergone repeated unsuccessful parathyroid exploration with inability to localise residual parathyroid tissue; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid tissue is surgically inaccessible; or </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">3.3.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Parathyroid surgery is not feasible and cinacalcet treatment is to be used as a bridge to kidney transplantation.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">\xa0</span></p><p class=""ql-indent-1""><b style=""font-size: 9pt;"">Renewal – (secondary or tertiary hyperparathyroidism)</b><span style=""font-size: 9pt;""> from any relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Either:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Both:</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Following initial treatment with cinacalcet, the patient has had a cinacalcet treatment-free interval of at least 12 weeks; and</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0</span><span style=""font-size: 9pt;"">Cinacalcet is indicated after reassessment of parathyroid function performed at least 6 months after cinacalcet cessation; or</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">\xa0A trial of withdrawal of cinacalcet is clinically inappropriate.</span></p><p>1.3.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>In making this recommendation, the Committee considered:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The indirect evidence consistent with improved mortality</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The lack of strong evidence for quality-of-life benefits from cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The side effect profile of cinacalcet</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The added benefit of another medicine for management of calcium and phosphate in this patient population.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that Pharmac should seek advice from the Nephrology Subcommittee regarding the Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism, and considered that the Nephrology Subcommittee’s view on the proposed renewal criteria for patients who may benefit from cinacalcet retreatment following a period off cinacalcet treatment, where appropriate, would be valuable.</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered cinacalcet for primary, secondary and tertiary hyperparathyroidism to support Pharmac’s assessment of these proposals.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><b>Background</b></p><p>1.1.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the long history of clinical advice regarding cinacalcet for hyperparathyroidism from the Endocrinology Subcommittee, the Nephrology Subcommittee and PTAC, described on the Pharmac Application Tracker items for <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008ptsL/p000137"" target=""_blank"">primary hyperparathyroidism</a>, <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puCp/p000744"" target=""_blank"">secondary hyperparathyroidism</a> and <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P000008puPm/p000985"" target=""_blank"">tertiary hyperparathyroidism</a>. The Committee noted the following in particular:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf"" target=""_blank"">July 2008</a>, PTAC had recommended that hyperparathyroidism (any cause) be declined for listing in the Pharmaceutical Schedule</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-endocrinology-subcommittee-minutes-2014-06-17.pdf"" target=""_blank"">June 2014</a>, the Endocrinology Subcommittee noted a recommendation from the New Zealand Society of Endocrinology to fund cinacalcet for patients with primary hyperparathyroidism who have significant/symptomatic hypercalcaemia (&gt;3mmol/L) and cannot be treated surgically</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2014-12.pdf"" target=""_blank"">December 2014</a> the Nephrology Subcommittee\xa0recommended cinacalcet for listing in the Pharmaceutical Schedule for secondary and tertiary hyperparathyroidism with calciphylaxis with a medium priority</p><p class=""ql-indent-1""><span style=""font-size: 11pt; font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 11pt;"">In May 2016, cinacalcet was listed on the Pharmaceutical Schedule for </span><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/notification-of-decision-to-fund-cinacalcet-sensipar-for-parathyroid-carcinoma-and-calciphylaxis/"" target=""_blank"" style=""font-size: 11pt;"">patients with parathyroid carcinoma and symptomatic calciphylaxis,</a><span style=""font-size: 11pt;""> subject to </span><a href=""https://schedule.pharmac.govt.nz/2021/03/01/SA1618.pdf"" target=""_blank"" style=""font-size: 11pt;"">Special Authority criteria</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommitee-minutes-2016-12.pdf"" target=""_blank"">December 2016</a>, the Nephrology Subcommittee reiterated its previous recommendation with regards to proposed Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/ptac-nephrology-subcommittee-minutes-2018-03.pdf"" target=""_blank"">March 2018</a>, the Nephrology Subcommittee considered that access to cinacalcet should be widened to include patients with hyperparathyroidism and kidney disease subject to clinical criteria</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In <a href=""https://pharmac.govt.nz/assets/2021-03-30-Endocrinology-Subcommittee-Records-Web-Version.pdf"" target=""_blank"">March 2021</a>, the Endocrinology Subcommittee considered it was reasonable for cinacalcet to be funded for people with primary hyperparathyroidism with severe hypercalcemia who are not deemed operable, and have no available alternative treatments; that a reduction in calcium to less than 3.0 mmol/L was clinically meaningful and a critical outcome for the target group of patients; and that it was reasonable to infer, based on the evidence of benefits (including reduction in mortality) from calcium level reduction (from surgery and from the use of cinacalcet in several hypercalcaemic states), that cinacalcet could result in clinically meaningful benefits from a calcium level reduction in people with primary hyperparathyroidism who are not deemed operable.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that cinacalcet is a modulator of the calcium sensing receptor. It decreases parathyroid hormone levels by increasing the receptor sensitivity to extracellular calcium. The Committee noted that cinacalcet is approved by Medsafe to treat:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis as adjunctive therapy</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>hypercalcaemia in adult patients with parathyroid carcinoma</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>primary hyperparathyroidism in adult patients for whom parathyroidectomy is not a treatment option.</p><p>1.3.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that cinacalcet has long been included within international treatment guidelines and considered no new primary evidence to be available since past reviews of these proposals by the Subcommittees. The Committee considered that the existing clinical trial evidence had been used extensively in meta-analyses and noted that some new meta-analyses and registry descriptive data had been identified.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that for primary hyperparathyroidism, the estimated number of patients who require hospital care was uncertain and that there was a lack of agreement in the estimates of benefit across outcome measures. The Committee considered similarly that for secondary and tertiary hyperparathyroidism there was also a lack of agreement in the estimates of benefit across outcome measures.</p><p><b>Secondary and tertiary hyperparathyroidism</b></p><p>1.5.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that secondary hyperparathyroidism is characterised by excessively high parathyroid hormone levels as a response to prolonged hypocalcaemia or hyperphosphataemia, often due to renal insufficiency. The Committee noted that tertiary hyperparathyroidism develops from long-standing, uncontrolled secondary hyperparathyroidism despite correction (or attempted correction) of hypercalcaemia and hyperphosphataemia, for example in patients with end-stage renal disease of several years&#39; duration.</p><p>1.6.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that Māori and Pacific peoples with secondary hyperparathyroidism on dialysis have a high health need and experience health inequities arising from increased incidence of kidney disease and low kidney transplant rates. The Committee considered that kidney transplant is an effective treatment for secondary hyperparathyroidism if performed before disease becomes severe and is the preferred treatment option for secondary/tertiary hyperparathyroidism. The Committee noted best supportive care is the current treatment for patients with secondary/tertiary hyperparathyroidism who have had, or are unsuitable for, a kidney transplant. However, the Committee considered that this supportive care is associated with poor outcomes.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0</span>Members noted that cinacalcet therapy for secondary/tertiary hyperparathyroidism has been referred to as ‘medical parathyroidectomy’ due to its therapeutic intent.</p><p>1.8.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that there was little new evidence of relevance available since cinacalcet was last considered for secondary and tertiary hyperparathyroidism by Pharmac’s clinical advisory committees, and noted that previous concerns were around the estimates of benefit across outcome measures.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of the <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340919/"" target=""_blank"">Kidney Disease: Improving Global Outcomes (KDIGO) 2017 Clinical Practice Guideline update</a>, which did not recommend cinacalcet in chronic kidney disease but did recommended cinacalcet as initial therapy in patients with secondary hyperparathyroidism on dialysis. The Committee noted that KDIGO 2017 did not specifically recommend cinacalcet for tertiary hyperparathyroidism, and noted that cinacalcet is not Medsafe approved for hyperparathyroidism post-transplant but acknowledged that it is used in this setting. The Committee noted that <a href=""https://www.uptodate.com/contents/management-of-secondary-hyperparathyroidism-in-adult-dialysis-patients?search=secondary+hyperparathyroidism&amp;source=search_result&amp;selectedTitle=2%7E135&amp;usage_type=default&amp;display_rank=2"" target=""_blank"">UpToDate (July 2021)</a> did not recommend cinacalcet in chronic kidney disease, however UpToDate did recommend cinacalcet for patients with secondary hyperparathyroidism on dialysis following unsuccessful management of calcium and phosphate levels and does not give advice for tertiary hyperparathyroidism.</p><p>1.10.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a large (n=3,526) inception cohort of patients in Sweden with chronic kidney disease in 2006–2012 (both non-dialysis, dialysis and transplanted) with evidence of secondary hyperparathyroidism who were followed up for median 37 months (<a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794851/"" target=""_blank"">Evans et al. Sci Rep. 2018;8:2103</a>). The Committee noted that 12% of patients commenced cinacalcet and the authors had reported this treatment was associated with trends towards an all-cause mortality advantage (adjusted odds ratio 0.79; 95%CI: 0.56 to 1.11), ascribed mostly to a reduction in the odds of fatal/non-fatal cardiovascular events (odds ratio 0.67; 95%CI: 0.48 to 0.93).</p><p>1.11.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a randomised, open label study in chronic haemodialysis patients (n=45) with severe secondary hyperparathyroidism that explored the effect of cinacalcet on chronic kidney disease-mineral bone disorder parameters including calcium (<a href=""https://www.tandfonline.com/doi/full/10.1080/0886022X.2018.1562356"" target=""_blank"">Susantitaphong et al. Ren Fail. 2019;41:326-33</a>). The Committee noted the authors reported that cinacalcet was associated with a reduction in parathyroid hormone levels and a benefit in bone mineral markers.</p><p>1.12.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted two meta-analyses that included randomised controlled trial evidence and long-term (up to 7 years) observational data for patients on dialysis, which concluded that cinacalcet reduced all-cause mortality vs placebo in secondary hyperparathyroidism (<span style=""color: black;"">relative risk [RR] 0.91, 95% CI 0.89-0.94, </span><i style=""color: black;"">P</i><span style=""color: black;""> &lt; 0.001; </span><a href=""https://www.karger.com/?DOI=10.1159/000504139"" target=""_blank"">Zu et al. Kidney Blood Press Res. 2019;44:1327-38</a><span style=""color: black;"">; hazard ratio: 0.83; 95% credible interval: 0.78–0.89; </span><a href=""https://www.futuremedicine.com/doi/full/10.2217/cer-2018-0015"" target=""_blank"">Lozano-Ortega et al. J Comp Eff Res. 2018;7:693-707</a><span style=""color: black;"">).</span></p><p>1.13.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted a meta-analysis of generally short-term (less than two years’ follow-up) randomised controlled trial evidence in patients with secondary hyperparathyroidism in chronic kidney disease, which reported that cinacalcet administration did not reduce all-cause mortality vs placebo (RR = 0.97, 95% CI = 0.89-1.05, <i>P </i>= 0.41; <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29449603/"" target=""_blank"">Wang et al. Sci Rep. 2018;8:3111</a>). However, members noted that a large proportion of data in the meta-analysis came from one study (EVOLVE) that reported no mortality advantage overall but did report in sub-population analysis a mortality advantage in patients over 60 years of age (<a href=""https://www.nejm.org/doi/full/10.1056/nejmoa1205624#article_letters"" target=""_blank"">The EVOLVE trial Investigators. N Engl J Med 2012;367:2482-94</a><span style=""color: black;"">). The Committee has previously noted various issues with the EVOLVE trial including its post-hoc subgroup analyses (</span><a href=""https://pharmac.govt.nz/assets/ptac-minutes-2016-05.pdf"" target=""_blank"">PTAC May 2016 record paragraph 8.24</a><span style=""color: black;"">).</span></p><p>1.14.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a systematic review and meta-analysis of long-term mortality after parathyroidectomy or medical treatment from cohort studies including over 20,000 chronic kidney disease patients with secondary hyperparathyroidism, which reported a reduction in all-case death (HR 0.72) and in cardiovascular death (HR 0.63) with surgery (<a href=""https://www.tandfonline.com/doi/full/10.1080/0886022X.2016.1184924"" target=""_blank"">Chen et al. Ren Fail. 2016;38:1050-8</a><span style=""color: black;"">). Members considered the number of patients who received cinacalcet was likely low given the enrolment to the individual trials could have ceased in about 2013 and that the survival benefit </span>reported for surgery over cinacalcet likely underestimated the benefit of cinacalcet as a medical parathyroidectomy.</p><p>1.15.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a meta-analysis of eight randomised controlled trials, which concluded that cinacalcet reduces serum calcium and serum phosphate but not parathyroid hormone parameters in patients with secondary hyperparathyroidism on dialysis and reported no unexpected safety signals with cinacalcet and vitamin D (<a href=""https://doi.org/10.1007/s11255-019-02271-6"" target=""_blank"">Xu et al. Int Urol Nephrol. 2019;51:2027-36</a>). Members noted however that a large proportion of data in the meta-analysis was derived from one study which investigated intravenous treatment with another agent.</p><p>1.16.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of observational evidence from the limited European Dialysis Outcomes and Practice Patterns Study (DOPPS) registry compared with real-world descriptive data which suggested an increase in five-year survival with optimal management across several factors including serum albumin (which was key), phosphate, haemoglobin, vascular access and fluids in a population with\xa0predominantly secondary hyperparathyroidism on dialysis (<a href=""https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-019-1251-z#citeas"" target=""_blank"">Combe et al. BMC Nephrol. 2019;20:81</a>). Members considered cinacalcet may support management of phosphate levels in this setting and that phosphate management was likely associated with a mortality benefit.\xa0</p><p>1.17.<span style=""font-size: 7pt;"">\xa0</span>The Committee was made aware of earlier, observational data from the DOPPS registry reporting that very high and very low parathyroid hormone levels were associated with increased mortality in patients on dialysis (HR for death 1.09; <a href=""https://cjasn.asnjournals.org/cgi/pmidlookup?view=long&amp;pmid=25516917"" target=""_blank"">Tentori et al. Clin J Am Soc Nephrol. 2015;10:98-109).</a></p><p>1.18.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted evidence from a randomised trial of different surgical approaches to parathyroidectomy. This study reported substantial changes from baseline in the physical and mental component summary scores of the SF-36 that did not differ for the different types of surgery (<a href=""https://www.sciencedirect.com/science/article/abs/pii/S0039606018303763?via%3Dihub"" target=""_blank"">Filho et al. Surgery. 2018;164:978-85</a>). However, the Committee considered that this was not direct evidence for an improvement in quality of life with cinacalcet in secondary (or tertiary) hyperparathyroidism, as cinacalcet was not compared to surgery in that study, and that while cinacalcet may be considered a medical parathyroidectomy, any quality-of-life benefit of cinacalcet would be subject to significant uncertainty.</p><p>1.19.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the meta-analyses in tertiary hyperparathyroidism were of lesser quality due to their cohort study design constituents, although considered that the large Swedish cohort study reported by <a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794851/"" target=""_blank"">Evans et al. (Sci Rep. 2018;8:2103</a>) was of good quality.</p><p>1.20.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted that a small (n=24) randomised cohort study comparing parathyroidectomy with cinacalcet for treating tertiary hyperparathyroidism reported normalised serum calcium levels in 7 of 11 patients (64%) in the parathyroidectomy group and 6 of 13 patients (46%) in the cinacalcet group (<i>P</i>=0.44) after five years (<a href=""https://doi.org/10.1111/ctr.13988"" target=""_blank"">Moreno et al. Clin Transplant. 2020;34:e13988</a>). The Committee noted that there were no differences observed in kidney function and the incidence of fragility fractures between both groups.</p><p>1.21. The Committee noted evidence from a single centre, retrospective cohort study of patients with tertiary hyperparathyroidism (<i>N</i>=83, of which 52 received observation alone, 13 received cinacalcet treatment and 18 received parathyroidectomy), and noted that the main determinant of management was the magnitude of elevated serum calcium (<a href=""https://journals.lww.com/transplantjournal/Fulltext/2012/07150/Tertiary_Hyperparathyroidism_in_Kidney_Transplant.11.aspx?casa_token=nB2FUdJc644AAAAA:p7QDHuZg4iSkBQ8RSbnRlJE6mZ9BDOOMmQ_9CHwmqqzwoDmpqnr2jGNoWdNMKTGh6eCOwOGMFPpBMwkk3YjXSFA"" target=""_blank"">Yang et al. Transplantation 2012;15: 70-6</a>). The Committee noted evidence that reported 38% of transplanted patients had elevated parathyroid hormone levels 9-12 months post-transplant; and of these, 63% were observed and the remainder received cinacalcet with or without surgery (<a href=""https://www.sciencedirect.com/science/article/abs/pii/S0039606015007357?casa_token=5GIVcUD3zjAAAAAA:x4oTW8S9LkoDmLTTV7_ANwcB2Y-7-z3I4eWziQ_2CjNbuwrf1WeoyVRI6PG0f9cuIP7aShwK#bib1"" target=""_blank"">Lou et al. Surgery 2016;159: 172-80</a>). The Committee considered that this evidence suggests half of this patient group could be managed without an intervention.</p><p>1.22.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the evidence for tertiary hyperparathyroidism from small cohort studies added little to the evidence for cinacalcet in this setting.</p><p>1.23.<span style=""font-size: 7pt;"">\xa0</span>Overall, the Committee noted that there was no direct evidence of a mortality benefit from cinacalcet in secondary or tertiary hyperparathyroidism although there was indirect evidence of an association between reduced calcium levels and mortality. The Committee considered that outcomes associated with cinacalcet therapy were good relative to surgical outcomes and that this supported the concept of a mortality benefit from cinacalcet. The Committee considered that a mortality benefit was likely the most plausible outcome for patients with secondary hyperparathyroidism receiving cinacalcet. Members considered that cinacalcet may improve allograft survival post kidney transplant in patients with tertiary hyperparathyroidism, although there was an absence of new data to support this.</p><p>1.24.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the side effect profile of cinacalcet is well recognised with 10-30% of patients experiencing gastrointestinal upset that may lead to discontinuation.</p><p>1.25.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet could appropriately form part of the treatment approach for patients with secondary and tertiary hyperparathyroidism who are on dialysis, used as an extra therapy alongside existing treatments in the paradigm for a multi-modal approach to disease management. The Committee considered that serum calcium and phosphate levels are difficult to manage with currently available treatments, and that cinacalcet may make these easier to manage for patients with chronic kidney disease, with particular impact in the management of patients with secondary hyperparathyroidism.</p><p>1.26.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that, if cinacalcet was funded for secondary hyperparathyroidism, there may be a desire to access it prior to parathyroidectomy especially in patients who were seeking parathyroidectomy while awaiting a kidney transplant. The Committee considered that concerns regarding general anaesthesia may preclude parathyroid surgery as an option for some patients. The Committee considered that a small group may seek cinacalcet access post-surgery and that some patients may access cinacalcet prior to kidney transplant.</p><p>1.27.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet treatment would be ongoing for those deemed to be requiring it and receiving benefit from it, however, members noted that cinacalcet may not be needed long-term in patients with tertiary hyperparathyroidism whose elevated parathyroid hormone levels resolve post-transplant. The Committee considered parathyroid hormone levels would resolve post-transplant in about two-thirds of cases. The Committee considered it would be reasonable for cinacalcet to be subject to renewal criteria requiring assessment after a period off treatment to confirm the need for further cinacalcet treatment and appropriately target the intended population. The Committee considered that Pharmac should seek advice from the Nephrology Subcommittee regarding the Special Authority criteria for cinacalcet for secondary and tertiary hyperparathyroidism, and considered that the Subcommittee’s view on the proposed renewal criteria for patients who may benefit from cinacalcet retreatment following a period off cinacalcet treatment, where appropriate, would be valuable.</p><p>1.28.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted the Nephrology Subcommittee in 2014 had estimated that approximately 5% of dialysis patients would be eligible for cinacalcet treatment under the proposed criteria. The Committee considered these were likely to be an underestimate, and that it is possible over 50% of patients on dialysis may fit the proposed Special Authority criteria. The Committee considered that based on the surgery criteria in the proposed Special Authority criteria, cinacalcet may plausibly be used prior to surgery in some patients. The Committee considered that many of those that would benefit from cinacalcet in this setting would be Māori and Pacific peoples.</p><p>1.29.<span style=""font-size: 7pt;"">\xa0</span>The Committee noted Pharmac staff’s estimate of patient numbers for tertiary hyperparathyroidism, which assumed approximately 17% of patients developed tertiary hyperparathyroidism after renal transplant (<a href=""https://onlinelibrary.wiley.com/doi/full/10.1111/ajt.12911"" target=""_blank"">Evenepoel et al. Am J Transplant 2014;14: 2545-55</a>). The Committee considered it was uncertain what proportion of these patients would meet the proposed criteria for cinacalcet and therefore receive treatment, but that an estimate of 25% of these patients requiring cinacalcet was reasonable. The Committee considered that tertiary hyperparathyroidism would resolve itself within 12 months in a proportion of patients, and that the time on treatment would therefore be quite short for some patients.</p><p>1.30.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that cinacalcet may reduce the number of hospitalisations in patients with secondary and tertiary hyperparathyroidism, but any hospitalisation reduction would likely be small. The Committee considered it was plausible that cinacalcet may provide no additional quality-of-life benefits compared with standard of care in the setting of secondary hyperparathyroidism, noting the complex care required for this comorbid patient population. However, the Committee considered that any quality of life benefits would be valuable to patients on renal replacement therapy.</p><p>1.31.<span style=""font-size: 7pt;"">\xa0</span>The Committee considered that the below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for cinacalcet if it were to be funded in New Zealand for secondary hyperparathyroidism. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</p><table class=""ql-table-blob"" border=""0"" style=""width: 460.45pt;"" width=""614""><tbody><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal""><b>P</b><span style=""color: black;"">opulation </span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Patients on dialysis with symptomatic\n  secondary hyperparathyroidism and elevated PTH who are unable to receive\n  surgical treatment. </p></td></tr><tr style=""height: 17.65pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 17.65pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">I</span></b><span style=""color: black;"">ntervention</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 17.65pt;"" width=""514""><p class=""MsoNormal"" style="""">Cinacalcet, mean daily dose of 60 mg,\n  based on Nephrology Subcommittee advice in 2014</p></td></tr><tr style=""height: 3.4pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 3.4pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">C</span></b><span style=""color: black;"">omparator(s)</span></p><p class=""MsoNormal""><span style=""color: black;"">(NZ context)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 3.4pt;"" width=""514""><p class=""MsoNormal"" style="""">Best supportive care </p></td></tr><tr style=""height: 22.1pt;""><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 75.3pt; border: solid windowtext 1.0pt; height: 22.1pt;"" width=""100""><p class=""MsoNormal""><b><span style=""color: black;"">O</span></b><span style=""color: black;"">utcome(s)</span></p></td><td colspan=""1"" rowspan=""1"" valign=""top"" style=""width: 385.15pt; height: 22.1pt;"" width=""514""><p class=""MsoNormal"" style="""">Significant reduction in serum calcium and\n  serum phosphate</p><p class=""MsoNormal"" style="""">Probable but poorly-defined benefit on\n  mortality (most likely outcome), cardiovascular events and health-related\n  quality of life </p><p class=""MsoNormal"">Very small reduction in the need for hospitalisations to\n  correct hypercalcaemia</p><p class=""MsoNormal"">\xa0</p><p class=""MsoNormal"">Improved phosphate management, which may be associated\n  with mortality benefits </p></td></tr></tbody></table><p><br></p>', 'Status_History__c': 'a132P000000DOntQAG'}, 'change': None}]",Jul 2008,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2015', 'fs': 'Nov 2015', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRRUAY'}, 'Id': 'a0P2P000006pnRRUAY', 'Event_Date__c': '2015-11-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2015', 'Status_History__c': 'a132P000000Ar26QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRSUAY'}, 'Id': 'a0P2P000006pnRSUAY', 'Event_Date__c': '2016-02-10', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar4IQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2016', 'fs': 'Feb 2016', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRTUAY'}, 'Id': 'a0P2P000006pnRTUAY', 'Event_Date__c': '2016-02-11', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2016', 'Status_History__c': 'a132P000000Ar4pQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2016', 'fs': 'May 2016', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRYUAY'}, 'Id': 'a0P2P000006pnRYUAY', 'Event_Date__c': '2016-05-06', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2016', 'Status_History__c': 'a132P000000Ar8TQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2021', 'fs': 'Nov 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRjUAI'}, 'Id': 'a0P2P000006pnRjUAI', 'Event_Date__c': '2021-11-24', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2021', 'Status_History__c': 'a132P000000DMuUQAW'}, 'change': None}]",Nov 2015,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2016', 'fs': 'Mar 2016', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRUUAY'}, 'Id': 'a0P2P000006pnRUUAY', 'Event_Date__c': '2016-03-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2016', 'Status_History__c': 'a132P000000Ar6OQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2016', 'fs': 'Mar 2016', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRVUAY'}, 'Id': 'a0P2P000006pnRVUAY', 'Event_Date__c': '2016-03-29', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2016', 'Status_History__c': 'a132P000000Ar6fQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2016', 'fs': 'Jun 2016', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRZUAY'}, 'Id': 'a0P2P000006pnRZUAY', 'Event_Date__c': '2016-06-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2016', 'Status_History__c': 'a132P000000Ar9ZQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2021', 'fs': 'Dec 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRkUAI'}, 'Id': 'a0P2P000006pnRkUAI', 'Event_Date__c': '2021-12-14', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2021', 'Status_History__c': 'a132P000000DPxJQAW'}, 'change': None}]",Mar 2016,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-08-31-proposals-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/?page=3"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-08-31-proposals-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/?page=3"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2022', 'fs': 'Aug 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRlUAI'}, 'Id': 'a0P2P000006pnRlUAI', 'Event_Date__c': '2022-08-31', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-08-31-proposals-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/?page=3"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Aug 2022', 'Status_History__c': 'a132P000000E8cxQAC'}, 'change': None}]",Aug 2022,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRmUAI'}, 'Id': 'a0P2P000006pnRmUAI', 'Event_Date__c': '2022-09-16', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E8d2QAC'}, 'change': None}]",Sep 2022,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decisions-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decisions-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2022', 'fs': 'Nov 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006pnRnUAI'}, 'Id': 'a0P2P000006pnRnUAI', 'Event_Date__c': '2022-11-10', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-11-10-decisions-to-fund-treatments-for-people-with-kidney-disease-osteoporosis-cancers-hyperparathyroidism-and-injuries-from-burns/"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Nov 2022', 'Status_History__c': 'a132P000000EB57QAG'}, 'change': None}]",Nov 2022,False,True
